

ASIA VITAL COMPONENTS CO. , LTD
AND SUBSIDIARIES
CONSOLIDATED FINANCIAL STATEMENTS
WITH REPORT OF INDEPENDENT ACCOUNTANTS
FOR THE NINE-MONTH PERIODS ENDED
SEPTEMBER 30, 2025,AND 2024

Address: No.248-27, Xinsheng Rd., Qianzhen Dist., Kaohsiung City 806, Taiwan (R.O.C.)
Telephone: 886-7-815-7612

The reader is advised that these consolidated financial statements have been prepared originally in Chinese. In the event of a conflict between these financial statements and the original Chinese version or difference in interpretation between the two versions, the Chinese financial statements shall prevail.

REVIEW REPORT OF INDEPENDENT ACCOUNTANTS

English Translations of a Report Originally Issued in Chinese

To Asia Vital Components Co., Ltd.

Introduction

We have reviewed the accompanying consolidated balance sheets of Asia Vital Components Co., Ltd. and subsidiaries (collectively, the "Company ") as of September 30, 2025 and 2024, the related consolidated statements of comprehensive income for the three-month and nine-month periods ended September 30, 2025 and 2024 and consolidated statements of changes in equity and cash flows for the nine-month periods ended September 30, 2025 and 2024, and notes to the consolidated financial statements, including the summary of significant account policies (together "the consolidated financial statements"). Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, "Interim Financial Reporting" as endorsed and became effective by Financial Supervisory Commission of the Republic of China. Our responsibility is to express a conclusion on these consolidated financial statements based on our reviews.

Scope of Review

We conducted our reviews in accordance with the Standard on Review Engagements 2410 , "Review of Financial Information Performed by the Independent Auditor of the Entity" of the Republic of China. A review of consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with auditing standards generally accepted in the Republic of China and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Basis for Qualified Conclusion

As discussed in Note, certain non-significant subsidiaries included in the consolidated financial statements were unreviewed. These subsidiaries' total assets amounted to NT\$29,243,349 thousand and NT\$18,500,999 thousand, or 21% and 21% of the total consolidated assets as of September 30, 2025 and 2024, respectively. These subsidiaries' total liabilities amounted to NT\$19,532,410 thousand and NT\$10,292,537 thousand, or 20% and 18% of the total consolidated liabilities as of September 30, 2025 and 2024, respectively. The comprehensive income of these subsidiaries amounted to (NT\$620,598) thousand and NT\$485,124 thousand, or (8%) and 17% of the consolidated comprehensive income for the three-month periods ended September 30, 2025 and 2024, respectively.

The comprehensive income of these subsidiaries amounted to NT\$90,013 thousand and NT\$ 768,685 thousand, or 1% and 10% of the consolidated comprehensive income for the nine-month periods ended September 30, 2025 and 2024, respectively. As discussed in Note 6(9) to consolidated financial statements mentioned, the investments accounted for under the equity method were NT\$226,505 thousand and NT\$ 639,004 thousand as of September 30, 2025 and 2024 respectively. The share of income of associates under the equity method amounted to (NT\$18,226) thousand and NT\$26,164 thousand for the three-month periods ended September 30, 2025 and 2024, respectively. The share of income of associates under the equity method amounted to (NT\$104,998) thousand and NT\$97,835 thousand for the nine-month periods ended September 30, 2025 and 2024, respectively. The share of the other comprehensive income of associates under the equity method amounted to NT\$5,853 thousand and NT\$9,410 thousand for the three-month periods ended September 30, 2025 and 2024, respectively. The share of the other comprehensive income of associates under the equity method amounted to NT\$12,021 thousand and NT\$4,232 thousand for the nine-month periods ended September 30, 2025 and 2024, respectively. These amounts were based on the investees' unreviewed financial statements. The information on Note 13 to consolidated financial statements was not reviewed by the independent accountants.

Qualified Conclusion

Based on our reviews, except for the information of certain non-significant subsidiaries and investees mentioned in the Basis for Qualified Conclusion paragraph where were based on the unreviewed financial statements that might be adjusted if they were reviewed by the independent accountants, nothing has come to our attention that causes us to believe that the accompanying consolidated financial statements do not present fairly, in all material respects, the consolidated financial position of the Company and its subsidiaries as of September 30, 2025 and 2024, their consolidated financial performance for the three-month and nine-month periods ended September 30, 2025 and 2024, and cash flows for the nine-month periods ended September 30, 2025 and 2024, in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, "Interim Financial Reporting" as endorsed and became effective by Financial Supervisory Commission of the Republic of China.

ERNST & YOUNG

Taiwan

Republic of China

Nov 12, 2025

Notice to Readers

The accompanying consolidated financial statements are intended only to present the consolidated financial position, results of operations and cash flows in accordance with accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions, The standards, procedures and practices to review such consolidated financial statements are those generally accepted and applied in the Republic of China.

English translation of Consolidated Financial Statements Originally issued in Chinese
ASIA VITAL COMPONENTS CO., LTD
CONSOLIDATED BALANCE SHEETS
As of September 30, 2025, December 31, 2024 and September 30, 2024
(Expressed in thousands of New Taiwan Dollars)

Assets	Notes	September 30, 2025		December 31, 2024		September 30, 2024	
		Amount	%	Amount	%	Amount	%
Current assets							
Cash and cash equivalents	6(1)	\$43,788,642	31	\$29,923,508	30	\$30,012,780	34
Financial assets measured at amortized costs, current	6(2), 8	3,430,117	2	2,075,672	2	1,979,710	2
Notes receivable, net	4, 6(3)	1,548,956	1	1,305,637	1	804,729	1
Accounts receivable, net	4, 6(4)	7,186,119	5	6,461,331	6	5,468,847	6
Other receivables	6(4).(5)	1,087,857	1	533,799	1	696,820	1
Other receivables-related parties	6(5)	4,632	0	5,681	0	6,993	0
Inventories, net	6(6)	49,040,291	35	33,397,345	33	25,206,070	29
Prepayments	6(7)	1,059,987	1	751,509	1	602,142	1
Other current assets		2,167,575	2	1,637,875	2	1,161,429	1
Total current assets		109,314,176	78	76,092,357	76	65,939,520	75
Non-current assets							
Financial assets measured at fair value through other comprehensive income, noncurrent	4, 6(8)	473,298	1	493,663	1	484,196	1
Financial assets at amortized cost, noncurrent	6(2)	30,384	0	32,719	0	31,586	0
Investments accounted for under the equity method	6(9)	226,505	0	636,808	1	639,004	1
Property, plant and equipment	4, 6(10), 8	16,407,353	12	13,805,248	14	13,124,661	15
Right-of-use assets	4, 6(24)	3,041,207	2	3,019,998	3	2,922,099	3
Investment property	4, 6(11), 8	292,239	0	268,763	0	265,527	0
Intangible assets	6(12)	176,990	0	168,667	0	164,835	0
Deferred tax assets	4, 6(28)	1,778,323	1	1,296,010	1	1,252,106	1
Other non-current assets	6(13), 8	7,478,158	6	4,054,739	4	3,258,747	4
Net defined benefit assets, noncurrent	4, 6(20)	35,409	0	36,589	0	17,714	0
Total non-current assets		29,939,866	22	23,813,204	24	22,160,475	25
Total assets		\$139,254,042	100	\$99,905,561	100	\$88,099,995	100

(The accompanying notes are an integral part of the consolidated financial statements.)

English translation of Consolidated Financial Statements Originally issued in Chinese
ASIA VITAL COMPONENTS CO., LTD
CONSOLIDATED BALANCE SHEETS
As of September 30, 2025, December 31, 2024 and September 30, 2024
(Expressed in thousands of New Taiwan Dollars)

		September 30, 2025		December 31, 2024		September 30, 2024	
Liabilities and Equity	Notes	Amount	%	Amount	%	Amount	%
Current liabilities							
Short-term loans	6(14)	\$14,798,554	11	\$9,585,252	10	\$8,250,973	10
Short-term notes payable	6(15)	—	—	—	—	70,000	0
Contract liabilities, current	6(23)	2,132	0	2,881	0	2,909	0
Notes payable		7,243,047	5	5,192,111	5	4,283,662	5
Accounts payable		37,837,870	27	23,691,532	24	20,349,432	23
Other payables	6(16)	12,000,794	9	7,924,925	8	7,127,619	8
Current tax liabilities	4, 6(28)	5,047,854	4	2,491,022	2	1,821,933	2
Lease liabilities, current	4, 6(24)	368,637	0	335,637	0	273,899	0
Other current liabilities		8,873,470	6	5,520,145	5	3,979,556	5
Current portion of long-term liabilities	6(17),(18)	1,329,398	1	3,544,621	4	3,742,487	4
Total current liabilities		\$87,501,756	63	58,288,126	58	49,902,470	57
Non-current liabilities							
Long-term loans	6(18)	5,557,644	4	3,348,795	3	2,545,606	3
Deferred tax liabilities	4, 6(28)	2,175,153	2	2,135,455	2	2,106,039	2
Lease liabilities, noncurrent	4, 6(24)	1,779,679	1	1,960,515	2	1,913,607	2
Long-term deferred revenue	6(19)	610,544	0	661,136	1	674,755	1
Guarantee deposits		37,273	0	38,659	0	38,285	0
Total non-current liabilities		10,160,293	7	8,144,560	8	7,278,292	8
Total liabilities		97,662,049	70	66,432,686	66	57,180,762	65
Equity attributable to the parent company							
Capital	6(21)						
Common stock		3,881,796	3	3,875,535	4	3,833,101	4
Capital collected in advance		184,856	0	6,995	0	211,034	0
Additional paid-in capital	6(21)	2,568,951	2	3,546,404	4	3,377,804	4
Retained earnings	6(21)						
Legal reserve		3,117,584	2	2,298,983	2	2,298,983	3
Special reserve		609,162	1	1,451,514	2	1,451,514	2
Undistributed earnings		28,160,701	20	18,300,365	18	15,949,133	18
Total retained earnings		31,887,447	23	22,050,862	22	19,699,630	23
Other components of equity		(2,062,298)	(1)	(609,162)	(1)	(476,944)	(1)
Total equity attributable to the parent company		36,460,752	27	28,870,634	29	26,644,625	30
Non-controlling interests	6(21)	5,131,241	3	4,602,241	5	4,274,608	5
Total equity		41,591,993	30	33,472,875	34	30,919,233	35
Total liabilities and equity		\$139,254,042	100	\$99,905,561	100	\$88,099,995	100

(The accompanying notes are an integral part of the consolidated financial statements.)

English translation of Consolidated Financial Statements originally issued in Chinese
ASIA VITAL COMPONENTS CO., LTD
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
As of September 30, 2025, December 31, 2024 and September 30, 2024
(Expressed in thousands of New Taiwan Dollars, except for earnings per share)

Items	Notes	For the three-month period ended September 30, 2025		For the three-month period ended September 30, 2024		For the nine-month period ended September 30, 2025		For the nine-month period ended September 30, 2024	
		Amount	%	Amount	%	Amount	%	Amount	%
Operating revenues	4, 6(23)	\$38,936,900	100	\$19,064,683	100	\$91,864,360	100	\$50,857,226	100
Operating costs	6(24),(25)	(28,765,150)	(74)	(14,584,432)	(76)	(68,440,211)	(75)	(39,210,501)	(77)
Gross profit		10,171,750	26	4,480,251	24	23,424,149	25	11,646,725	23
Operating expenses	6(24),(25)								
Sales and marketing expenses		(362,297)	(1)	(244,203)	(2)	(1,077,944)	(1)	(753,393)	(1)
General and administrative expenses		(316,397)	(1)	(155,599)	(1)	(933,893)	(1)	(554,735)	(1)
Research and development expenses		(1,314,445)	(3)	(938,227)	(5)	(3,708,431)	(4)	(2,844,763)	(6)
Expected credit impairment (losses) gains		(93,306)	(0)	(34,345)	(0)	(163,124)	(0)	(24,065)	(0)
Subtotal		(2,086,445)	(5)	(1,372,374)	(8)	(5,883,392)	(6)	(4,176,956)	(8)
Operating income		8,085,305	21	3,107,877	16	17,540,757	19	7,469,769	15
Non-operating income and expenses									
Interest income	6(26)	136,453	0	127,265	1	421,164	0	376,190	1
Other income	6(26)	178,119	0	380,021	2	671,499	1	1,029,879	2
Other gains and losses	6(26)	(13,436)	(0)	(104,663)	(0)	638,544	1	34,660	0
Finance costs	6(26)	(151,267)	(0)	(109,084)	(1)	(433,516)	(1)	(315,910)	(1)
Share of profit or loss of associates	4, 6(9)	(18,226)	(0)	26,164	0	(104,998)	(0)	97,835	0
Subtotal		131,643	0	319,703	2	1,192,693	1	1,222,654	2
Income from continuing operations before income tax		8,216,948	21	3,427,580	18	18,733,450	20	8,692,423	17
Income tax expense	6(28)	(2,307,423)	(6)	(826,283)	(4)	(5,041,993)	(5)	(2,180,618)	(4)
Net income		5,909,525	15	2,601,297	14	13,691,457	15	6,511,805	13
Other comprehensive income (loss)	6(27)								
Items that will not be reclassified subsequently to profit or loss:									
Unrealized gains (losses) from equity instruments investments measured at fair value through other comprehensive income		91,931	0	(93,348)	(0)	(17,550)	(0)	246,750	0
Items that may be reclassified subsequently to profit or loss:									
Exchange differences on translation of foreign operations		1,365,853	4	415,769	2	(1,771,504)	(2)	1,026,073	2
Share of other comprehensive income (loss) of associates		5,853	0	9,410	0	12,021	0	4,232	0
Income tax related to items that may be reclassified subsequently		(37,772)	(0)	(94,251)	(1)	167,788	0	(208,872)	(0)
Total other comprehensive loss, net of tax		1,425,865	4	237,580	1	(1,609,245)	(2)	1,068,183	2
Total comprehensive income		\$7,335,390	19	\$2,838,877	15	\$12,082,212	13	\$7,579,988	15
Net income attributable to:									
Stockholders of the parent		\$5,339,300	14	\$2,323,510	12	\$12,550,451	14	\$5,834,782	12
Non-controlling interests		570,225	1	277,787	2	1,141,006	1	677,023	1
		\$5,909,525	15	\$2,601,297	14	\$13,691,457	15	\$6,511,805	13
Comprehensive income (loss) attributable to:									
Stockholders of the parent		\$6,627,910	17	\$2,527,954	13	\$11,097,315	12	\$6,809,352	13
Non-controlling interests		707,480	2	310,923	2	984,897	1	770,636	2
		\$7,335,390	19	\$2,838,877	15	\$12,082,212	13	\$7,579,988	15
Earnings per share (NTD)									
Earnings per share-basic		\$13.67		\$6.02		\$32.25		\$15.18	
Earnings per share-diluted	4, 6(29)	\$13.46		\$5.93		\$31.54		\$14.77	

(The accompanying notes are an integral part of the consolidated financial statements.)

English translation of Consolidated Financial Statements originally issued in Chinese
ASIA VITAL COMPONENTS CO., LTD
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
For the nine-month periods ended September 30, 2025 and 2024
(Expressed in thousands of New Taiwan Dollars)

Items	Equity Attributable to the Parent Company									Non-Controlling Interests	Total Equity
	Capital		Additional Paid-in Capital	Retained Earnings			Other Components of Equity		Total		
	Common Stock	Advance receipts for share capital		Legal Reserve	Special Reserve	Unappropriated Earnings	Exchange Differences on Translation of Foreign Operations	Unrealized Gains (Losses) From Equity Instruments Investments Measured At Fair Value Through Other Comprehensive Income			
Balance as of January 1, 2024	\$3,833,101	—	\$3,866,691	\$1,768,785	\$1,119,685	\$12,892,929	(\$1,126,528)	(\$324,986)	\$22,029,677	\$3,817,401	\$25,847,078
Appropriation and distribution of 2023 retained earnings											
Legal reserve				530,198		(530,198)			—		—
Special reserve reversed					331,829	(331,829)			—		—
Cash dividends						(1,916,551)			(1,916,551)		(1,916,551)
Donation from shareholders			212						212		212
Cash dividends distributed from capital surplus			(766,620)						(766,620)		(766,620)
Income for the nine-month period ended September 30, 2024						5,834,782			5,834,782	677,023	6,511,805
Other comprehensive income (loss) for the nine-month period ended September 30, 2024							718,094	256,476	974,570	93,613	1,068,183
Total comprehensive income (loss)	—	—	—	—	—	5,834,782	718,094	256,476	6,809,352	770,636	7,579,988
Share-based payment transaction		\$211,034	277,521						488,555		488,555
Decrease in non-controlling interests									—	(313,429)	(313,429)
Balance as of September 30, 2024	\$3,833,101	211,034	\$3,377,804	\$2,298,983	\$1,451,514	\$15,949,133	(\$408,434)	(\$68,510)	\$26,644,625	\$4,274,608	\$30,919,233
Balance as of January 1, 2025	\$3,875,535	6,995	\$3,546,404	\$2,298,983	\$1,451,514	\$18,300,365	(\$539,526)	(\$69,636)	\$28,870,634	\$4,602,241	\$33,472,875
Appropriation and distribution of 2024 retained earnings											
Legal reserve				818,601		(818,601)			—		—
Cash dividends						(2,713,866)			(2,713,866)		(2,713,866)
Special reserve reversed					(842,352)	842,352			—		—
Donation from shareholders			178						178		178
Cash dividends distributed from capital surplus			(1,163,086)						(1,163,086)		(1,163,086)
Income for the nine-month period ended September 30, 2025						12,550,451			12,550,451	1,141,006	13,691,457
Other comprehensive income (loss) for the nine-month period ended September 30, 2025							(1,435,586)	(17,550)	(1,453,136)	(156,109)	(1,609,245)
Total comprehensive income (loss)	—	—	—	—	—	12,550,451	(1,435,586)	(17,550)	11,097,315	984,897	12,082,212
Share-based payment transaction	6,261	177,861	185,455						369,577		369,577
Decrease in non-controlling interests									—	(455,897)	(455,897)
Balance as of September 30, 2025	\$3,881,796	\$184,856	\$2,568,951	\$3,117,584	\$609,162	\$28,160,701	(\$1,975,112)	(\$87,186)	\$36,460,752	\$5,131,241	\$41,591,993

(The accompanying notes are an integral part of the consolidated financial statements.)

English translation of Consolidated Financial Statements originally issued in Chinese
ASIA VITAL COMPONENTS CO., LTD
CONSOLIDATED STATEMENTS OF CASH FLOWS
For the nine-month periods ended September 30, 2025 and 2024
(Expressed in thousands of New Taiwan Dollars)

Items	For the nine-month period ended September 30, 2025	For the nine-month period ended September 30, 2024
Cash flows from operating activities:		
Net income before tax	\$18,733,450	\$8,692,423
Adjustments to reconcile net income before tax to net cash provided by operating activities:		
Income and expense adjustments :		
Depreciation	2,289,808	1,718,357
Amortization	41,128	60,466
Amortization of royalty	657	659
Amortization of patents	—	124
Expected credit losses	163,124	24,065
Interest expense	433,516	315,910
Interest income	(421,164)	(376,190)
Dividend income	(2,938)	(4,140)
Compensation costs of share-based payment transaction	160,788	277,521
Share of profit of associates	104,998	(97,835)
Loss on disposal of property, plant and equipment	104,691	107,426
(Gain) on disposal of investments accounted for using equity method	(10,601)	—
Impairment loss on non-financial assets	52,222	38,437
Others	2,642,349	1,211,924
Changes in operating assets and liabilities:		
Notes receivable	(242,194)	(21,123)
Accounts receivable	(1,253,758)	245,488
Other receivables	(176,008)	(38,512)
Other receivables-related parties	1,049	962
Inventories	(18,114,833)	(9,298,877)
Prepayments	(308,478)	(41,044)
Other current assets	(529,700)	(352,858)
Other operation assets	(1,354,445)	154,568
Contract liabilities	(749)	2,393
Notes payable	2,050,936	622,016
Accounts payable	14,146,338	5,238,032
Other payables	4,068,092	1,003,880
Other current liabilities	3,353,503	1,573,127
Net defined benefit liabilities	1,180	1
Cash generated from operations	<u>25,932,961</u>	<u>11,057,200</u>
Interest received	411,352	380,360
Interest paid	(425,739)	(319,351)
Income tax paid	<u>(2,759,988)</u>	<u>(2,157,024)</u>
Net cash provided by operating activities	<u>23,158,586</u>	<u>8,961,185</u>
Cash flows from investing activities:		
Acquisition of financial assets measured at fair value through other comprehensive income	—	(72,000)
Proceeds from disposal of financial assets at fair value through profit or loss	—	(225,526)
Proceeds from disposal of investments accounted for using equity method	217,314	—
Acquisition of property, plant and equipment	(5,523,619)	(3,015,963)
Proceeds from disposal of property, plant and equipment	2,348	5,759
(Increase) in refundable deposits	(84,124)	(29,037)
Acquisition of intangible assets	(55,670)	(43,296)
Acquisition of right-of-use assets	(289,162)	(155,620)
Acquisition of investment properties	—	(141,102)
(Increase) in other noncurrent assets-others	(2,953,391)	(1,662,926)
(Increase) in other prepayments	(387,492)	(2,029)
Dividends received	<u>2,938</u>	<u>14,912</u>
Net cash (used) in investing activities	<u>(9,070,858)</u>	<u>(5,326,828)</u>
Cash flows from financing activities:		
Increase in short-term loans	23,459,977	10,997,558
(Decrease) in short-term loans	(17,619,315)	(9,564,739)
Increase in short-term notes payable	—	40,000
Repayments of bonds	(2,400,000)	—
Proceeds from long-term loans	4,780,000	1,880,000
Repayments of long-term loans	(2,345,563)	(1,765,306)
(Decrease) Increase in guarantee deposits	(1,386)	2,782
Repayment of lease liabilities	(291,236)	(231,762)
Cash dividends	(3,876,952)	(2,683,171)
Proceeds from issuing shares	208,788	211,034
Change in non-controlling interests	(455,897)	(313,429)
Net cash provided (used) in financing activities	<u>1,458,416</u>	<u>(1,427,033)</u>
Effect of exchange rate changes on cash and cash equivalents	<u>(1,681,010)</u>	<u>848,487</u>
Net increase in cash and cash equivalents	<u>13,865,134</u>	<u>3,055,811</u>
Cash and cash equivalents at beginning of year	<u>29,923,508</u>	<u>26,956,969</u>
Cash and cash equivalents at end of year	<u>\$43,788,642</u>	<u>\$30,012,780</u>

(The accompanying notes are an integral part of the consolidated financial statements.)

English Translation of Financial Statements Originally Issued in Chinese
ASIA VITAL COMPONENTS CO., LTD AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2025 AND 2024
(Unless otherwise stated, all amounts expressed are in thousands of New Taiwan Dollars)

1. History and organization

ASIA VITAL COMPONENTS CO., LTD. (the Company) was incorporated on December 17, 1991. The Company's registered address is No.248-27, Xincheng Rd., Qianzhen Dist., Kaohsiung City. The principal activities of the Company are to manufacture, process, assemble and to import and export electronic parts, electronic materials, communication electronic machinery products, automobile parts, lighting device, computer peripherals.

The Company's ordinary shares were publicly listed on the Taiwan Stock Exchange (TWSE) on 27 September, 2002.

2. Date and procedures of authorization of financial statements for issue

The consolidated financial statements of the Company and its subsidiaries ("the Group") for the nine-month periods ended September 30, 2025 and 2024 were authorized for issue by the Board of Directors on Nov 12, 2025.

3. Newly issued or revised standards and interpretations

- (1) Changes in accounting policies resulting from applying for the first time certain standards and amendments.

The Group adopted International Financial Reporting Standards, International Accounting Standards, and Interpretations issued, revised or amended which are recognized by Financial Supervisory Commission ("FSC") and become effective for annual periods beginning on or after January 1, 2025. The adoption of these new standards and amendments had no material impact on the Group.

- (2) Standards or interpretations issued, revised or amended, by International Accounting Standards Board ("IASB") which have been endorsed by FSC, and not yet adopted by the Group as at the date when the Group's financial statements were authorized for issue, are listed below:

Items	New, Revised or Amended Standards and Interpretations	Effective Date issued by IASB
a	IFRS 17 "Insurance Contracts"	1 January 2023
b	Amendments to the Classification and Measurement of Financial Instruments – Amendments to IFRS 9 and IFRS 7	1 January 2026
c	Annual Improvements to IFRS Accounting Standards – Volume 11	1 January 2026
d	Contracts Referencing Nature-dependent Electricity – Amendments to IFRS 9 and IFRS 7	1 January 2026

A. IFRS 17 “Insurance Contracts”

IFRS 17 provides a comprehensive model for insurance contracts, covering all relevant accounting aspects (including recognition, measurement, presentation and disclosure requirements). The core of IFRS 17 is the General (building block) Model, under this model, on initial recognition, an entity shall measure a group of insurance contracts at the total of the fulfilment cash flows and the contractual service margin. The carrying amount of a group of insurance contracts at the end of each reporting period shall be the sum of the liability for remaining coverage and the liability for incurred claims.

Other than the General Model, the standard also provides a specific adaptation for contracts with direct participation features (the Variable Fee Approach) and a simplified approach (Premium Allocation Approach) mainly for short-duration contracts.

IFRS 17 was issued in May 2017 and it was amended in 2020 and 2021. The amendments include deferral of the date of initial application of IFRS 17 by two years to annual beginning on or after 1 January 2023 (from the original effective date of 1 January 2021); provide additional transition reliefs; simplify some requirements to reduce the costs of applying IFRS 17 and revise some requirements to make the results easier to explain. IFRS 17 replaces an interim Standard – IFRS 4 Insurance Contracts – from annual reporting periods beginning on or after 1 January 2023.

B. Amendments to the Classification and Measurement of Financial Instruments – Amendments to IFRS 9 and IFRS 7

The amendments include:

- (1) Clarify that a financial liability is derecognised on the settlement date and describe the accounting treatment for settlement of financial liabilities using an electronic payment system before the settlement date.
- (2) Clarify how to assess the contractual cash flow characteristics of financial assets that include environmental, social and governance (ESG)-linked features and other similar contingent features.
- (3) Clarify the treatment of non-recourse assets and contractually linked instruments.
- (4) Require additional disclosures in IFRS 7 for financial assets and liabilities with contractual terms that reference a contingent event (including those that are ESG-linked), and equity instruments classified at fair value through other comprehensive income.

C Annual Improvements to IFRS Accounting Standards – Volume 11

(1) Amendments to IFRS 1

The amendments mainly improve the consistency in wording between first-time adoption of IFRS and requirements for hedge accounting in IFRS 9.

(2) Amendments to IFRS 7

The amendments update an obsolete cross-reference relating to gain or loss on derecognition.

(3) Amendments to Guidance on implementing IFRS 7

The amendments improve some of the wordings in the implementation guidance, including the introduction, disclosure of deferred difference between fair value and transaction price and credit risk disclosures.

(4) Amendments to IFRS 9

The amendments add a cross-reference to resolve potential confusion for a lessee applying the derecognition requirements and clarify the term “transaction price”.

(5) Amendments to IFRS 10

The amendments remove the inconsistency between paragraphs B73 and B74 of IFRS 10.

(6) Amendments to IAS 7

The amendments remove a reference to “cost method” in paragraph 37 of IAS 7.

D. Contracts Referencing Nature-dependent Electricity – Amendments to IFRS 9 and IFRS 7

The amendments include:

(1) Clarify the application of the ‘own-use’ requirements.

(2) Permit hedge accounting if these contracts are used as hedging instruments.

(3) Add new disclosure requirements to enable investors to understand the effect of these contracts on a company’s financial performance and cash flows.

The abovementioned standards and amendments are applicable for annual periods beginning on or after 1 January 2026 and have no material impact on the Group.

- (3) Standards or interpretations issued, revised or amended, by International Accounting Standards Board (“IASB”) which have not been endorsed by FSC, and not yet adopted by the Group as at the date when the Group’s financial statements were authorized for issue, are listed below:

Items	New, Revised or Amended Standards and Interpretations	Effective Date issued by IASB
a	IFRS 10 “Consolidated Financial Statements” and IAS 28 “Investments in Associates and Joint Ventures” — Sale or Contribution of Assets between an Investor and its Associate or Joint Ventures	To be determined by IASB
b	IFRS 18 “Presentation and Disclosure in Financial Statements”	1 January 2027 (Note)
c	Disclosure Initiative – Subsidiaries without Public Accountability: Disclosures (IFRS 19)	1 January 2027

Note: On 25 September 2025, the FSC announced in a press release that Taiwan will adopt IFRS 18 in 2028.

A. IFRS 10 “Consolidated Financial Statements” and IAS 28 “Investments in Associates and Joint Ventures” — Sale or Contribution of Assets between an Investor and its Associate or Joint Ventures

The amendments address the inconsistency between the requirements in IFRS 10 *Consolidated Financial Statements* and IAS 28 *Investments in Associates and Joint Ventures*, in dealing with the loss of control of a subsidiary that is contributed to an associate or a joint venture. IAS 28 restricts gains and losses arising from contributions of non-monetary assets to an associate or a joint venture to the extent of the interest attributable to the other equity holders in the associate or joint ventures. IFRS 10 requires full profit or loss recognition on the loss of control of the subsidiary. IAS 28 was amended so that the gain or loss resulting from the sale or contribution of assets that constitute a business as defined in IFRS 3 between an investor and its associate or joint venture is recognized in full.

IFRS 10 was also amended so that the gains or loss resulting from the sale or contribution of a subsidiary that does not constitute a business as defined in IFRS 3 between an investor and its associate or joint venture is recognized only to the extent of the unrelated investors’ interests in the associate or joint venture.

B. IFRS 18 “Presentation and Disclosure in Financial Statements”

IFRS 18 replaces IAS 1 Presentation of Financial Statements. The main changes are as below:

(1) Improved comparability in the statement of profit or loss (income statement)

IFRS 18 requires entities to classify all income and expenses within their statement of profit or loss into one of five categories: operating; investing; financing; income taxes; and discontinued operations. The first three categories are new, to improve the structure of the income statement, and requires all entities to provide new defined subtotals, including operating profit or loss. The improved structure and new subtotals will give investors a consistent starting point for analyzing entities’ performance and make it easier to compare entities.

(2) Enhanced transparency of management-defined performance measures

IFRS 18 requires entities to disclose explanations of those entity-specific measures that are related to the income statement, referred to as management-defined performance measures.

(3) Useful grouping of information in the financial statements

IFRS 18 sets out enhanced guidance on how to organize information and whether to provide it in the primary financial statements or in the notes. The changes are expected to provide more detailed and useful information. IFRS 18 also requires entities to provide more transparency about operating expenses, helping investors to find and understand the information they need.

C. Disclosure Initiative – Subsidiaries without Public Accountability: Disclosures (IFRS 19)

This new standard and its amendments permits subsidiaries without public accountability to provide reduced disclosures when applying IFRS Accounting Standards in their financial statements. IFRS 19 is optional for subsidiaries that are eligible and sets out the disclosure requirements for subsidiaries that elect to apply it.

The abovementioned standards and interpretations issued by IASB have not yet endorsed by FSC at the date when the Group’s financial statements were authorized for issue, the local effective dates are to be determined by FSC. As the Group is still currently determining the potential impact of the new or amended standards and interpretations listed under and (b), it is not practicable to estimate their impact on the Group at this point in time. The remaining new or amended standards and interpretations have no material impact on the Group.

4. Summary of significant accounting policies

(1) Statement of compliance

The consolidated financial statements of the Group for the nine-month periods ended September 30, 2025 and 2024 have been prepared in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers (“the Regulations”) and IAS 34 Interim Financial Reporting as endorsed and became effective by the FSC.

(2) Basis of preparation

The consolidated financial statements have been prepared on a historical cost basis, except for financial instruments that have been measured at fair value. The consolidated financial statements are expressed in thousands of New Taiwan Dollars (“NT\$”) unless otherwise stated.

(3) Basis of consolidation

Preparation principle of consolidated financial statements

The Group's consolidated financial statements preparation principles are the same as the 2024 consolidated financial statements. Please refer to the Group's 2024 consolidated financial statements.

The consolidated entities are listed as follows:

Investor	Subsidiary	Main businesses	Percentage of ownership (%)		
			2025.9.30	2024.12.31	2024.9.30
The Group	AVC INTERNATIONAL CO., LTD.— B.V.I. (AVCI—BVI)	Investment holding	100.00%	100.00%	100.00%
	CHIHUNG INTERNATIONAL LTD. (CHIHUNG)	Investment holding	100.00%	100.00%	100.00%
	RAYNEY INTERNATIONAL LTD. (RAYNEY)	Trade	100.00%	100.00%	100.00%
	MERIT TRADING CORPORATION (MERIT)	Trade	100.00%	100.00%	100.00%
	AVC AMERICA, INC. (AVCA)	Trade	100.00%	100.00%	100.00%
	AVC INTERNATIONAL (SAMOA) CO., LTD. (AVCI(SAMOA))	Trade	100.00%	100.00%	100.00%
	JADS CORPORATION (HK) LTD. (JADS)	Trade	100.00%	100.00%	100.00%
	AVC INTERNATIONAL CO., LTD.— SAMOA (AVCI—SAMOA)	Trade	100.00%	100.00%	100.00%
	HUNG YE INVESTMENT CO., LTD. (HUNGYE)	Investment holding	100.00%	100.00%	100.00%

Investor	Subsidiary	Main businesses	Percentage of ownership (%)		
			2025.9.30	2024.12.31	2024.9.30
	D-MAX TECHNOLOGY CO.,LTD. (D-MAX)	Sales and manufacture of electronic parts and related products	100.00%	100.00%	100.00%
	FOSITEK CORP. (FOSITEK)	Sales and manufacture of electronic parts and related products	16.87%	16.87%	16.87%
	AVC EUROPE TECHNOLOGY GMBH (AVCEU)	Trade	100.00%	100.00%	100.00%
	AVC TECHNOLOGY (VIETNAM) COMPANY LIMITED. (AVC(VN))	Sales and manufacture of electronic products	100.00%	100.00%	100.00%
AVCI – BVI	ASIA VITAL COMPONENTS (SHEN ZHEN) CO.,LTD. (AVCSZ)	Sales and manufacture of electronic products	100.00%	100.00%	100.00%
	MACE TECH CORP. (MACE)	Trade	100.00%	100.00%	100.00%
	ASIA VITAL COMPONENTS (CHENGDU) CO.,LTD. (AVCCD)	Sales and manufacture of computers, related parts and accessories	100.00%	100.00%	100.00%
	AVC OPTICS CORP. (AVCOC)	Investment holding	100.00%	100.00%	100.00%
MACE	ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD. (AVCDG)	Manufacture, process and sales of electronic products	100.00%	100.00%	100.00%
AVCDG	AVC PRECISION, CO., LTD.	Manufacture, sales of electronic products	100.00%	100.00%	100.00%
AVCOC	AVC OPTICS (WUHAN) CORP. (AVCWH)	Sales and manufacture of computers, related parts and accessories	100.00%	100.00%	100.00%
AVCWH	WUHAN ASIA VITAL COMPONENTS CO.,LTD. (AVCWN)	Trade	100.00%	100.00%	100.00%
CHIHUNG	ASIA VITAL COMPONENTS (CHINA) CO.,LTD. (AVCCN)	Sales and manufacture of electronic products	100.00%	100.00%	100.00%

Investor	Subsidiary	Main businesses	Percentage of ownership (%)		
			2025.9.30	2024.12.31	2024.9.30
AVCCN	BEIJING AVC TECHNOLOGY RESEARCH CENTER CO., LTD. (AVCBJ)	Maintenance, research and development of electronic products	100.00%	100.00%	100.00%
D-MAX	WUCHIDA INTERNATIONAL CO., LTD.(WUCHIDA)	Investment holding	100.00%	100.00%	100.00%
WUCHIDA	D-Max INTERNATIONAL CO., LIMITED (D-Max)	Investment holding	100.00%	100.00%	100.00%
D-Max	(JIASHAN) D-MAX ELECTRONICS CO.,LTD	Sales and manufacture of electronic and photographic equipment	100.00%	100.00%	100.00%
FOSITEK	MARKETHILL INVESTMENTS LIMITED (MARKETHILL)	Investment holding	100.00%	100.00%	100.00%
	FOSITEK (VIETNAM) COMPANY LIMITED	Sales and manufacture of rails and hinges	100.00%	100.00%	100.00%
	FOSITEK AMERICA, INC.	Sales of hinges	100.00%	100.00%	100.00%
MARKETHILL	SHENZHEN FOSITEK TELECOM CO.LTD.	Sales and manufacture of rails, hinges and metal stamping tooling	100.00%	100.00%	100.00%
SHENZHEN FOSITEK TELECOM CO.LTD.	DONGGUAN FOSITEK TELECOM CO.,LTD.	Sales and manufacture of hinges	100.00%	100.00%	100.00%

Although the percentage of ownership interests in FOSITEK is less than 50%, the Group determined that it has control over FOSITEK. This is due to a combination of factors : the Group remains the single largest shareholder of FOSITEK since the increase of the investment in September 2014, the Group could obtain proxies to achieve relative majority in the absence of a contractual arrangement in place; and the ability of the Company to appoint or approve the key management personnel of FOSITEK who have the ability to direct the relevant activities.

The financial statements of part of the consolidated subsidiaries listed above had not been reviewed by auditors. As of September 30, 2025 and 2024, the related assets of the subsidiaries which were unaudited by auditors amount to \$29,243,349 thousand and \$18,500,999 thousand respectively, and the related liabilities amount to \$19,532,410 thousand and \$10,292,537 thousand, respectively. The comprehensive income of these subsidiaries amount to (\$620,598) thousand and \$485,124 thousand for the three-month periods ended September 30, 2025 and 2024, respectively. The comprehensive income of these subsidiaries amount to \$90,013 thousand and \$768,685 thousand for the nine-month periods ended September 30, 2025 and 2024, respectively.

(4) Basis of consolidation

The accounting policies adopted by the Group in the consolidated financial statements from January 1 to September 30, 2025 are the same as the consolidated financial statements of 2024. For the summary of other important accounting policies, please refer to the Group's 2024 consolidated financial statements.

5. Significant accounting judgements, estimates and assumptions

The major sources of significant accounting judgments, estimates and assumptions that are used in the Group's consolidated financial statements for the period from January 1 to September 30 2025 and 2024 are the same as the 2024 consolidated financial statements. Please refer to the Group's 2024 consolidated financial statements.

6. Contents of significant accounts

(1) Cash and cash equivalents

	30 Sep 2025	31 Dec 2024	30 Sep 2024
Cash on hand and demand deposits	\$35,828,643	\$24,253,788	\$23,140,135
Time deposits	7,959,999	5,669,720	6,838,935
Securities purchased under resell agreements	—	—	33,710
Total	<u>\$43,788,642</u>	<u>\$29,923,508</u>	<u>\$30,012,780</u>

Cash and cash equivalents were not pledged.

(2) Financial assets measured at amortized cost, current

<u>Current:</u>	30 Sep 2025	31 Dec 2024	30 Sep 2024
Bank deposits	\$3,430,117	\$2,075,672	\$1,979,710
 Noncurrent:			
Bond	30,384	32,719	31,586
Total	<u>\$3,460,501</u>	<u>\$2,108,391</u>	<u>\$2,011,296</u>

The Group classified certain financial assets as financial assets measured at amortized cost. Please refer to Note 8 for more details on financial assets measured at amortized cost under pledge and Note 12 for details on credit risk and assessment of impairment loss.

(3) Notes receivable, net

A.

	30 Sep 2025	31 Dec 2024	30 Sep 2024
Notes receivable	\$1,549,668	\$1,307,474	\$806,914
Less: loss allowance	(712)	(1,837)	(2,185)
Total	<u>\$1,548,956</u>	<u>\$1,305,637</u>	<u>\$804,729</u>

B. Notes receivables arising from operating activities and were not pledged.

- C. The Group follows the requirement of IFRS 9 to assess the impairment. The Group measures the loss allowance of its note receivables at an amount equal to lifetime expected credit losses. The movement in the provision for impairment of note receivables is as follows:

Movement of the loss allowance table:

	Loss allowance
As of 1 Jan 2025	\$1,837
(Reversal) for the current period	(971)
Foreign exchange adjustments	(154)
As of 30 Sep 2025	\$712
As of 1 Jan 2024	\$1,459
Charge for the current period	631
Foreign exchange adjustments	95
As of 30 Sep 2024	\$2,185

(4) Accounts receivable, net

A.

	30 Sep 2025	31 Dec 2024	30 Sep 2024
Account receivables	\$7,611,001	\$6,730,156	\$5,705,197
Less: loss allowance	(424,882)	(268,825)	(236,350)
Total	\$7,186,119	\$6,461,331	\$5,468,847

B. Accounts receivables were not pledged.

- C. Trade receivables are generally on 90-150 day terms. The total carrying amount as of September 30, 2025, December 31, 2024 and September 30, 2024 were \$7,611,001 thousand, \$6,730,156 thousand and \$5,705,197 thousand, respectively. The Group follows the requirement of IFRS 9 to assess the impairment, measure the loss allowance of its trade receivables at an amount equal to lifetime expected credit losses, consider the grouping of note receivables by counterparties' credit rating, by geographical region and by industry sector, and its loss allowance is recognized based on expected loss ratio, details are as follow.

	Neither past due nor impaired	Past due but not impaired			Total
		31~90 days	91~180 days	>=181 days	
30 Sep 2025					
Gross carrying amount	\$7,569,255	\$10,113	\$1,346	\$30,287	\$7,611,001
Loss ratio	0%~5%	1%~10%	5%~20%	50%~100%	
Lifetime expected credit losses	394,932	101	67	29,782	424,882
Subtotal	\$7,174,323	\$10,012	\$1,279	\$505	\$7,186,119
31 Dec 2024					
Gross carrying amount	\$6,692,112	\$5,002	\$108	\$32,934	\$6,730,156
Loss ratio	0%~5%	1%~10%	5%~20%	50%~100%	
Lifetime expected credit losses	235,835	50	6	32,934	268,825
Subtotal	\$6,456,277	\$4,952	\$102	—	\$6,461,331
30 Sep 2024					
Gross carrying amount	\$5,662,888	\$4,324	\$1,656	\$36,329	\$5,705,197
Loss ratio	0%~5%	1%~10%	5%~20%	50%~100%	
Lifetime expected credit losses	201,382	43	83	34,842	236,350
Subtotal	\$5,461,506	\$4,281	\$1,573	\$1,487	\$5,468,847

D. Movement of the loss allowance table:

	Collectively impaired
As of 1 Jan 2025	\$268,825
Charge for the current period	158,964
Foreign exchange adjustments	(2,907)
As of 30 Sep 2025	<u>\$424,882</u>
Charge	
As of 1 Jan 2024	\$209,392
Charge for the current period	23,383
Foreign exchange adjustments	3,575
As of 30 Sep 2024	<u>\$236,350</u>

- E. The Group entered into a factoring agreement with the following banks to sell its accounts receivable. Under the agreement, the Group is not obligated to bear the default risk of the transferred accounts receivable but is liable for the losses incurred on any business dispute. The Group does not have any continuing involvement in the transferred accounts receivable. Thus, the Group derecognized the transferred accounts receivable.

As of 30 September 2025, 31 December 2024 and 30 September 2024, other receivables from banks incurred by accounts receivable factoring amounted to \$682,793 thousand, \$309,879 thousand and \$466,278 thousand, respectively.

As of 30 September 2025, 31 December 2024 and 30 September 2024, the relevant information of accounts receivable factored and derecognised by the Group is as follows:

(a) 30 September 2025:

The Factor (Transferee)	Interest Rate (%)	Accounts receivable factoring not yet due (in thousands)	Amount received (in thousands)	Retention (recognized as other receivables) (in thousands)	Credit Limit (in thousands)
E.SUN	—	\$22,427	—	\$22,427	\$100,000
CTBC	—	—	—	—	12,000
Total		<u>\$22,427</u>	<u>—</u>	<u>\$22,427</u>	<u>\$112,000</u>

(b) 31 December 2024:

The Factor (Transferee)	Interest Rate (%)	Accounts receivable factoring not yet due (in thousands)	Amount received (in thousands)	Retention (recognized as other receivables) (in thousands)	Credit Limit (in thousands)
E.SUN	—	\$9,452	—	\$9,452	\$100,000
CTBC	—	—	—	—	12,000
Total		<u>\$9,452</u>	<u>—</u>	<u>\$9,452</u>	<u>\$112,000</u>

(c) 30 September 2024:

The Factor (Transferee)	Interest Rate (%)	Accounts receivable factoring not yet due (in thousands)	Amount received (in thousands)	Retention (recognized as other receivables) (in thousands)	Credit Limit (in thousands)
E.SUN	—	\$13,116	—	\$13,116	\$100,000
CTBC	—	1,616	—	1,616	20,000
Total		<u>\$14,732</u>	<u>—</u>	<u>\$14,732</u>	<u>\$120,000</u>

(5) Other receivables and other receivables-related parties

A.

	30 Sep 2025	31 Dec 2024	30 Sep 2024
Tax refund receivable	\$156,974	\$79,345	\$53,942
Other receivables	267,745	159,556	193,706
Other Receivables - Others	682,793	309,879	466,278
Less: loss allowance	(19,655)	(14,981)	(17,106)
Subtotal	1,087,857	533,799	696,820
Other receivables — related parties	4,632	5,681	6,993
Total	\$1,092,489	\$539,480	\$703,813

B. The Group follows the requirement of IFRS 9 to assess the impairment. The Group measures the loss allowance of its other receivables at an amount equal to lifetime expected credit losses, considers the grouping of note receivables by counterparties' credit rating, by geographical region and by industry sector and its loss allowance is recognized based on expected loss ratio, details are as follow. Please refer to Note 12 for more details on credit risk management.

C. Movement of the loss allowance table:

	Collectively impaired
As of 1 Jan 2025	\$14,981
Charge for the current period	5,131
Foreign exchange adjustments	(457)
As of 30 Sep 2025	\$19,655
As of 1 Jan 2024	\$16,622
Charge for the current period	51
Foreign exchange adjustments	433
As of 30 Sep 2024	\$17,106

(6) Inventories

A.

	30 Sep 2025	31 Dec 2024	30 Sep 2024
Raw materials	\$6,770,584	\$5,321,602	\$4,870,876
Work in progress	4,914,887	3,058,229	2,574,741
Finished goods	37,354,820	25,017,514	17,760,453
Total	\$49,040,291	\$33,397,345	\$25,206,070

B. Expenses and losses incurred on inventories for the nine-month periods ended September 30 2025 and 2024 were as follows:

	For the three-month periods ended September 30		For the nine-month periods ended September 30	
	2025	2024	2025	2024
Cost of inventories sold	\$27,303,497	\$13,945,646	\$65,777,548	\$37,977,731
Loss on inventory valuation	1,192,027	473,127	2,061,091	865,625
Loss on disposal of Inventory	269,626	165,659	601,572	367,145
Cost of goods sale	\$28,765,150	\$14,584,432	\$68,440,211	\$39,210,501

C. No inventories were pledged.

(7) Prepayments

	30 Sep 2025	31 Dec 2024	30 Sep 2024
Payment in advance	\$950,293	\$671,009	\$513,354
Other prepaid expenses	109,694	80,500	88,788
Total	<u>\$1,059,987</u>	<u>\$751,509</u>	<u>\$602,142</u>

(8) Financial assets at fair value through other comprehensive income, noncurrent

	30 Sep 2025	31 Dec 2024	30 Sep 2024
Debt instrument investments measured at fair value through other comprehensive income – Non-current:			
Listed companies stocks	\$318,987	\$368,257	\$359,227
Unlisted companies stocks	154,311	125,406	124,969
Total	<u>\$473,298</u>	<u>\$493,663</u>	<u>\$484,196</u>

Financial assets at fair value through other comprehensive income were not pledged.

(9) Investments accounted for under the equity method

A. The following table lists the investments in associates of the Group:

Investees	30 Sep 2025		31 Dec 2024		30 Sep 2024	
	Carrying amount	Percentage of ownership (%)	Carrying amount	Percentage of ownership (%)	Carrying amount	Percentage of ownership (%)
Investments in associates:						
ZIMAG TECHNOLOGY CO., INC. (Note 1)	—	—	\$51,803	9.53%	\$50,796	9.53%
FURUKAWA AVC ELECTRONICS (SUZHOU) CO., LTD.	182,753	30.00%	203,406	30.00%	198,473	30.00%
ZHUZHOU CRRC-AVC THERMAL TECHNOLOGY CO., LTD.	—	—	126,745	25.00%	123,063	25.00%
KEY APPLICATION TECHNOLOGY CO., LTD. (Note 2)	—	16.31%	—	16.31%	—	16.31%
PARAGON SEMICONDUCTOR LIGHTING TECHNOLOGY CO., LTD. (Note 3)	21,250	16.67%	39,171	40.00%	40,533	40.00%
DINGDAO ZHILIAN (BEILJING) (Note 4)	22,502	12.50%	215,683	12.50%	226,139	12.50%
Total	<u>\$226,505</u>		<u>\$636,808</u>		<u>\$639,004</u>	

Note1:The Group evaluated and concluded that it has significant influence over ZIMAG TECHNOLOGY CO., INC., thus, this investment of the Group used the equity method for evaluation.

Note2: The Group evaluated and concluded that it has significant influence over KEY APPLICATION TECHNOLOGY CO., LTD., thus, this investment of the Group used the equity method for evaluation.

Note3:The Group evaluated and concluded that it has significant influence over PARAGON SEMICONDUCTOR LIGHTING TECHNOLOGY CO., LTD., thus, this investment of the Group used the equity method for evaluation.

Note4:The Group evaluated and concluded that it has significant influence over DINGDAO ZHILIAN (BEILJING), thus, this investment of the Group used the equity method for evaluation.

Investments accounted for using the equity method of the Company and its subsidiaries, were \$226,505 thousand, \$636,808 thousand and \$639,004 thousand as of 30 September 2025, 31 December 2024 and 30 September 2024, respectively. For the three-month periods ended 30 September 2025 and 2024 and for the nine-month periods ended 30 September 2025 and 2024, the related shares of investment (loss) income from the associates were (\$18,226)thousand, \$26,164 thousand, (\$104,998) thousand and \$97,835 thousand, respectively. The related shares of other comprehensive income from the associates were \$5,853 thousand, \$9,410 thousand, \$12,021 thousand and \$4,232 thousand, which were based on the unaudited financial statements of those investee companies, without review by other accountants.

None of the aforementioned associates were pledged.

B. Financial information of associates:

There is no individually significant associate for the Group. When an associate is a foreign operation, and the functional currency of the foreign entity is different from the Group, an exchange difference arising from translation of the foreign entity will be recognized in other comprehensive income (loss).

The aggregate financial information of the Group's investments in its joint ventures is as follows:

	For the three-month periods ended September 30		For the nine-month periods ended September 30	
	2025	2024	2025	2024
Net income (loss)	(\$18,226)	\$26,164	(\$104,998)	\$97,835
Other comprehensive income (loss)	5,853	9,410	12,021	4,232
Total comprehensive income	<u>(\$12,373)</u>	<u>\$35,574</u>	<u>(\$92,977)</u>	<u>\$102,067</u>

(10) Property, plant and equipment

	30 Sep 2025	31 Dec 2024	30 Sep 2024
Owner occupied property, plant and equipment	<u>\$16,407,353</u>	<u>\$13,805,248</u>	<u>\$13,124,661</u>

A. Owner occupied property, plant and equipment

	Land	Buildings	Machinery and equipment	Molding equipment	Other facilities	Construction in progress and equipment awaiting examination	Total
Cost:							
As of 1 Jan 2025	\$167,151	\$3,570,716	\$10,094,089	\$1,161,925	\$5,411,504	\$2,543,343	\$22,948,728
Additions	—	1,198,424	3,427,101	313,761	1,371,530	(787,197)	5,523,619
Disposals	—	—	(120,893)	(27,649)	(146,769)	—	(295,311)
Transfers and reclassifications	—	(56,194)	—	—	—	—	(56,194)
Exchange differences	—	(234,263)	(565,996)	(88,546)	(318,484)	(192,540)	(1,399,829)
As of 30 Sep 2025	<u>\$167,151</u>	<u>\$4,478,683</u>	<u>\$12,834,301</u>	<u>\$1,359,491</u>	<u>\$6,317,781</u>	<u>\$1,563,606</u>	<u>\$26,721,013</u>
Depreciation and impairment:							
As of 1 Jan 2025	—	\$940,004	\$4,294,397	\$876,301	\$3,032,778	—	\$9,143,480
Depreciation	—	99,604	824,924	212,920	777,310	—	1,914,758
Impairment loss	—	—	52,222	—	—	—	52,222
Disposals	—	—	(73,639)	(25,447)	(119,654)	—	(218,740)
Transfers and reclassifications	—	(24,097)	—	—	—	—	(24,097)
Exchange differences	—	(41,918)	(275,120)	(57,444)	(179,481)	—	(553,963)
As of 30 Sep 2025	<u>—</u>	<u>\$973,593</u>	<u>\$4,822,784</u>	<u>\$1,006,330</u>	<u>\$3,510,953</u>	<u>—</u>	<u>\$10,313,660</u>

	Land	Buildings	Machinery and equipment	Molding equipment	Other facilities	Construction in progress and equipment awaiting examination	Total
Cost:							
As of 1 Jan 2024	\$167,151	\$3,808,129	\$8,471,565	\$925,344	\$4,313,056	\$1,509,626	\$19,194,871
Additions	—	75,607	1,365,680	120,765	854,463	599,448	3,015,963
Disposals	—	(446,006)	(256,926)	(22,097)	(107,186)	—	(832,215)
Transfers and reclassifications	—	(24,963)	—	—	—	—	(24,963)
Exchange differences	—	194,937	289,126	57,612	156,644	32,604	730,923
As of 30 Sep 2024	\$167,151	\$3,607,704	\$9,869,445	\$1,081,624	\$5,216,977	\$2,141,678	\$22,084,579
Depreciation and impairment:							
As of 1 Jan 2024	—	\$1,173,509	\$3,550,303	\$712,591	\$2,408,368	—	\$7,844,771
Depreciation	—	87,497	659,318	132,354	567,636	—	1,446,805
Impairment loss	—	—	38,437	—	—	—	38,437
Disposals	—	(382,997)	(161,338)	(22,097)	(87,903)	—	(654,335)
Transfers and reclassifications	—	(6,502)	—	—	—	—	(6,502)
Exchange differences	—	51,665	128,282	28,893	81,902	—	290,742
As of 30 Sep 2024	—	\$923,172	\$4,215,002	\$851,741	\$2,970,003	—	\$8,959,918
Net carrying amount as of:							
30 Sep 2025	\$167,151	\$3,505,090	\$8,011,517	\$353,161	\$2,806,828	\$1,563,606	\$16,407,353
31 Dec 2024	\$167,151	\$2,630,712	\$5,799,692	\$285,624	\$2,378,726	\$2,543,343	\$13,805,248
30 Sep 2024	\$167,151	\$2,684,532	\$5,654,443	\$229,883	\$2,246,974	\$2,141,678	\$13,124,661

B. The Group has evaluated the value of some machinery and equipment has been impaired, and impairment losses are recognized amounted to NT\$52,222 thousand and NT\$38,437 thousand for the years ended 30 September 2025 and 30 September 2024. The recoverable amount is the difference between fair value and disposal cost, this fair value measurement is categorized under Level 3.

C. Please refer to Note 8 for more details on property, plant and equipment under pledge.

(11) Investment property

Investment property includes the Group's own occupied investment property and the investment property held by the Group with the right-of-use assets. The Group enters into commercial property leasing contracts for its own investment property with a leasing period ranging from 1 to 10 years. The lease contract includes provisions for adjusting the rent based on the annual market environment.

	Land	Buildings	Total
Cost :			
As of 1 Jan 2025	\$131,910	\$247,845	\$379,755
Additions	—	—	—
Transfers and reclassifications	—	56,194	56,194
Exchange differences	—	(5,475)	(5,475)
As of 30 Sep 2025	<u>\$131,910</u>	<u>\$298,564</u>	<u>\$430,474</u>
As of 1 Jan 2024	\$8,769	\$191,772	\$200,541
Additions	123,141	17,961	141,102
Transfers and reclassifications	—	24,963	24,963
Exchange differences	—	4,663	4,663
As of 30 Sep 2024	<u>\$131,910</u>	<u>\$239,359</u>	<u>\$371,269</u>
Depreciation and impairment:			
As of 1 Jan 2025	—	\$110,992	\$110,992
Depreciation	—	4,481	4,481
Transfers and reclassifications	—	24,097	24,097
Exchange differences	—	(1,335)	(1,335)
As of 30 Sep 2025	<u>—</u>	<u>\$138,235</u>	<u>\$138,235</u>
As of 1 Jan 2024	—	\$94,903	\$94,903
Depreciation	—	3,293	3,293
Transfers and reclassifications	—	6,502	6,502
Exchange differences	—	1,044	1,044
As of 30 Sep 2024	<u>—</u>	<u>\$105,742</u>	<u>\$105,742</u>
Net carrying amount as at:			
As of 30 Sep 2025	<u>\$131,910</u>	<u>\$160,329</u>	<u>\$292,239</u>
As of 31 Dec 2024	<u>\$131,910</u>	<u>\$136,853</u>	<u>\$268,763</u>
As of 30 Sep 2024	<u>\$131,910</u>	<u>\$133,617</u>	<u>\$265,527</u>

	For the three-month periods		For the nine-month periods	
	ended September 30		ended September 30	
	2025	2024	2025	2024
Rental income from investment property	\$8,135	\$7,176	\$24,682	\$19,587
Less: Direct operating expenses from Investment property generating rental income	(2,046)	(1,781)	(6,146)	(4,931)
Total	<u>\$6,089</u>	<u>\$5,395</u>	<u>\$18,536</u>	<u>\$14,656</u>

Please refer to Note 8 for more details on investment property under pledge.

The investment property held by the Group is industrial land and buildings, and the fair value is equivalent to the carrying value.

(12) Intangible assets

	Computer software	Patents	License fee	Goodwill	Total
Cost:					
As of 1 Jan 2025	\$567,908	\$5,313	\$25,679	\$7,107	\$606,007
Addition	55,670	—	—	—	55,670
Disposals	(6,161)	(1,500)	(15,406)	—	(23,067)
Transfers and reclassifications	—	—	—	—	—
Exchange differences	(19,091)	(6)	—	—	(19,097)
As of 30 Sep 2025	<u>\$598,326</u>	<u>\$3,807</u>	<u>\$10,273</u>	<u>\$7,107</u>	<u>\$619,513</u>
As of 1 Jan 2024	\$494,922	\$5,185	\$25,679	\$7,107	\$532,893
Addition	43,172	124	—	—	43,296
Disposals	(481)	—	—	—	(481)
Transfers and reclassifications	—	—	—	—	—
Exchange differences	11,585	5	—	—	11,590
As of 30 Sep 2024	<u>\$549,198</u>	<u>\$5,314</u>	<u>\$25,679</u>	<u>\$7,107</u>	<u>\$587,298</u>
Amortization and impairment:					
As of 1 Jan 2025	\$402,016	\$5,313	\$22,904	\$7,107	\$437,340
Amortization	39,540	—	657	—	40,197
Disposals	(6,103)	(1,500)	(15,406)	—	(23,009)
Transfers and reclassifications	—	—	—	—	—
Exchange differences	(11,999)	(6)	—	—	(12,005)
As of 30 Sep 2025	<u>423,454</u>	<u>\$3,807</u>	<u>\$8,155</u>	<u>\$7,107</u>	<u>\$442,523</u>

	Computer software	Patents	License fee	Goodwill	Total
As of 1 Jan 2024	\$322,001	\$5,185	\$22,026	\$7,107	\$356,319
Amortization	59,152	124	659	—	59,935
Disposals	(353)	—	—	—	(353)
Transfers and reclassifications	—	—	—	—	—
Exchange differences	6,557	5	—	—	6,562
As of 30 Sep 2024	<u>\$387,357</u>	<u>\$5,314</u>	<u>\$22,685</u>	<u>\$7,107</u>	<u>\$422,463</u>
Net carrying amount as at:					
30 Sep 2025	<u>\$174,872</u>	<u>—</u>	<u>\$2,118</u>	<u>—</u>	<u>\$176,990</u>
31 Dec 2024	<u>\$165,892</u>	<u>—</u>	<u>\$2,775</u>	<u>—</u>	<u>\$168,667</u>
30 Sep 2024	<u>\$161,841</u>	<u>—</u>	<u>\$2,994</u>	<u>—</u>	<u>\$164,835</u>

Amortization expense of intangible assets under the statement of comprehensive income:

	For the three-month periods ended September 30		For the nine-month periods ended September 30	
	2025	2024	2025	2024
Operating costs	<u>\$2,738</u>	<u>\$2,423</u>	<u>\$8,359</u>	<u>\$7,044</u>
Operating expenses	<u>\$12,344</u>	<u>\$16,851</u>	<u>\$31,838</u>	<u>\$52,891</u>

(13) Other non-current assets

	30 Sep 2025	31 Dec 2024	30 Sep 2024
Advance payments in equipments	\$6,597,924	\$3,645,682	\$2,901,688
Refundable deposits	360,155	276,031	223,571
Other advance	516,281	128,789	128,789
Other non-current assets - other	3,798	4,237	4,699
Total	<u>\$7,478,158</u>	<u>\$4,054,739</u>	<u>\$3,258,747</u>

Please refer to Note 8 for more details on other non-current assets under pledge.

(14) Short-term borrowings

A.

	30 Sep 2025	31 Dec 2024	30 Sep 2024
Unsecured bank loans	<u>\$14,798,554</u>	<u>\$9,585,252</u>	<u>\$8,250,973</u>

B. Interest rate ranges are within 1.7000%~5.0200% , 1.7000%~5.7700% and 1.7000%~6.0900% as of 30 Sep 2025, 31 December 2024 and 30 Sep 2024, respectively.

C. As of 30 Sep 2025, 31 December 2024 and 30 Sep 2024, unused short-term lines of credit were \$23,603,578 thousand, \$16,785,825 thousand and \$18,000,277 thousand, respectively.

(15) Short-term notes and bills payable

property	Guarantee or acceptance agency	30 Sep 2025	31 Dec 2024	30 Sep 2024
Commercial papers payable	Mega Bills Finance CO., LTD.	—	—	\$70,000
Range of interest rates		—	—	1.868%

(16) Other payables

	30 Sep 2025	31 Dec 2024	30 Sep 2024
Salaries and bonus	\$4,917,562	\$3,421,320	\$3,100,463
Employee's compensation and remuneration of directors	1,192,689	539,700	637,155
Others	5,890,543	3,963,905	3,390,001
Total	\$12,000,794	\$7,924,925	\$7,127,619

(17) Corporate Bonds payable

	30 Sep 2025	31 Dec 2024	30 Sep 2024	Collateral
5 year secured bonds - issued at par value. Issued in August 2020. Interest at 0.62%, bullet repayment, payable annually.	—	\$2,400,000	\$2,400,000	Bank guarantee
Less: current portion	—	(2,400,000)	(2,400,000)	
Ending balance	—	—	—	

The issuance of the above corporate bonds payable is to repay existing loans and expand working capital, the Company entered into a syndicated credit facility agreement with 9 banks by E.SUN Commercial Bank, Taiwan Cooperative Bank, Hua Nan Commercial Bank, Bank of Taiwan, Land Bank of Taiwan, Mega International Commercial Bank, The Shanghai Commercial & Savings Bank, First Commercial Bank and CTBC Bank for a NT\$2,424,000 thousand credit line.

(18) Long-term borrowings

As of September 30, 2025、December 31, 2024 and September 30, 2024, the details of long-term borrowings are as follows:

Type of borrowing	September 30, 2025	Interest rate	Repayment period and method
Taipei Fubon Bank Syndicated bank loans	\$2,400,000	2.1602%	Fubon Syndicated Loan 14 banks, with a revolving utilization period starting from 13 Jun 2025 for 5 years .
Unsecured bank loans	4,487,042	1.6100%~ 5.1500%	Successively due by October 2030 (repay in installments) °
Subtotal	6,887,042		
Less: current portion	(1,329,398)		
Net amount	\$5,557,644		

Type of borrowing	December 31, 2024	Interest rate	Repayment period and method
Unsecured bank loans	\$4,493,416	1.6048%~ 5.6600%	Successively due by October 2030 (repay in installments) °
Subtotal	\$4,493,416		
Less: current portion	(1,144,621)		
Net amount	\$3,348,795		

Type of borrowing	September 30, 2024	Interest rate	Repayment period and method
Unsecured bank loans	\$3,888,093	1.7100%~ 6.2000%	Successively due by May 2029 (repay in installments) °
Subtotal	\$3,888,093		
Less: current portion	(1,342,487)		
Net amount	\$2,545,606		

The Company signed a “syndicated secured loan contract,” amounting to USD\$150,000 thousand, with the group of syndicated loan banks, including Taipei Fubon Bank and E.SUN BANK, arranged and organized by Taipei Fubon Bank on September 19, 2024. The purposes of the loans are repayments of borrowings from financial institutions and enhancement of mid-term operating capital. As of September 30, 2025, the actual usage amount is NT\$2,400,000 thousand, and the amount not used is NT\$2,166,750 thousand.

Aside from the relevant regulations in the syndicated secured loan contract, there are limitations as follows: in the duration of the syndicated loans before full repayment, the financial ratios shall be maintained as follows, and the ratios shall be calculated by the financial statements audited by CPA half a year:

- A. Current ratio [current assets/current liabilities]: maintain at least 100% (included)
- B. Debt-to-equity ratio [liabilities less cash less cash equivalents / Total consolidated shareholders' equity]: maintain lower than 250% (included)
- C. Tangible net value (shareholders' equity less intangible assets): At least NT\$8 billion.
- D. Ratio of Interest Coverage Ratio [net income before interest expenses, taxation, depreciation, amortization, interest expenses/ interest expenses]: maintain at a ratio of 5 or above.

The Company shall abide by requirements of specific financial ratios, including current ratio, debt-to-equity ratio, tangible net value and ratio of Interest coverage ratio. As of September 30, 2025, the Company did not violate the aforementioned terms of regulations.

(19) Long-term deferred revenue

Government grants were as follows:

	For the nine-month periods ended September 30	
	2025	2024
Beginning balance	\$661,136	\$665,737
Released to the statement of comprehensive income	(20,251)	(20,835)
Exchange differences	(30,341)	29,853
Ending balance	\$610,544	\$674,755

Government grants have been received for the purchase of certain items of property, plant and equipment.

(20) Post-employment benefits

A. Defined contribution plan

Expenses under the defined contribution plan for the three-month periods ended 30 September 2025 and 2024 are \$10,105 thousand and \$9,384 thousand, respectively; for the nine-month periods ended 30 September 2025 and 2024 are \$29,670 thousand and \$27,402 thousand, respectively.

B. Defined benefits plan

Costs under the defined benefits plan for the three-month periods ended 30 September 2025 and 2024 are \$1,139 thousand and \$662 thousand, respectively; for the nine-month periods ended 30 September 2025 and 2024 are \$3,102 thousand and \$1,987 thousand, respectively.

(21) Equities

A. Common stock

As of 30 September 2025, 31 December 2024 and 30 September 2024, the Group's authorized capital was \$6,000,000 thousand, and issued \$3,881,796 thousand, issued \$3,875,535 thousand, and issued \$3,833,101 thousand with 388,180 thousand shares, 387,554 thousand shares, and 383,310 thousand shares each at a par value of \$10. Each share has one voting right and a right to receive dividends.

In the second quarter of 2025, the Company has delivered 12 thousand ordinary shares with a par value of NT\$10 per share due to the exercise of stock options by employees, and as of September 30, 2025, Relevant regulators' approvals have been obtained and related registration processes have been completed.

In the third quarter of 2025, the Company has delivered 2,533 thousand ordinary shares with a par value of NT\$10 per share due to the exercise of stock options by employees. The aforementioned newly issued shares (NT\$184,856 thousand in the amount) were not yet registered and therefore were classified as capital collected in advance as of September 30, 2025.

B. Additional paid-in capital

	30 Sep 2025	31 Dec 2024	30 Sep 2024
Share premium	\$844,568	\$1,982,987	\$1,814,388
Difference between consideration and carrying amount of subsidiaries acquired or disposed	83,185	83,185	83,185
Changes in ownership interests in subsidiaries	253,379	253,379	253,379
Donated assets received	4,027	3,849	3,849
Premium from merger	443,730	443,730	443,730
Employee stock option	916,770	755,982	755,981
Share options of convertible bonds	23,292	23,292	23,292
Total	<u>\$2,568,951</u>	<u>\$3,546,404</u>	<u>\$3,377,804</u>

According to the Company Act, the capital reserve shall not be used except for making good the deficit of the company. When a company incurs no loss, it may distribute the capital reserves related to the income derived from the issuance of new shares at a premium or income from endowments received by the company. The distribution could be made in cash or in the form of dividend shares to its shareholders in proportion to the number of shares being held by each of them.

C. Retained earnings and dividend policies

According to the Company's Articles of Incorporation, current year's earnings, if any, shall be distributed in the following order:

- (a) Payment of all taxes and dues;
- (b) Offset prior years' operation losses;
- (c) Set aside 10% of the remaining amount after deducting items (a) and (b) as legal reserve, except for when accumulated legal reserve has reached total authorized capital.
- (d) Set aside or reverse special reserve in accordance with law and regulations; and
- (e) The distribution of the remaining portion, if any, will be recommended by the Board of Directors and resolved in the shareholders' meeting.
- (f) According to Paragraph 5, Article 240 of the Company Act, the resolution authorizing a majority vote at a meeting of Board of Directors attended by two-thirds of the total number of directors shall, in the form of the distribution of dividends and dividends or all or part of the legal reserves and capital reserves provided for in Paragraph 1, Article 241 of the Companies Act, shall be paid in cash and shall be reported to the shareholders' meeting.

The policy of dividend distribution should reflect factors such as the current and future development plan, investment environment, fund requirements, domestic and international competition as well as the interest of the shareholders. A percentage of no less than 5% of the distributable profits of the accounting period shall be distributed as shareholders' dividends annually. When the accumulated distributable profits are less than 10% of our paid-up capital, we will no longer be required to make allowances for allocation. Shareholders' dividends could be paid in the form of shares or cash. Accordingly, at least 10% of the dividends must be paid in the form of cash.

According to the Company Act, the Company needs to set aside an amount to legal reserves unless where such legal reserve amounts to the total authorized capital. The legal reserve can be used to make good the deficit of the Company. When the Company incurs no loss, it may distribute the portion of legal reserves that exceeds 25% of the paid-in capital by issuing new shares or by cash in proportion to the number of shares being held by each of the shareholders.

Following the adoption of TIFRS, the FSC on 31 March 2021 issued Order No. Financial-Supervisory-Securities-Corporate-1090150022, which sets out the following provisions for compliance: On a public company's first-time adoption of the TIFRS, for any unrealized revaluation gains and cumulative translation adjustments (gains) recorded to shareholders' equity that the company elects to transfer to retained earnings by application of the exemption under IFRS 1, the company shall set aside an equal amount of special reserves. Following a company's adoption of the TIFRS for the preparation of its financial reports, when distributing distributable earnings, it shall set aside to special reserves, from the profit/loss of the current period and the undistributed earnings from the previous period. The amount should equal to "other net deductions from shareholders' equity for the current fiscal year, provided that the company has already set aside special reserves according to the requirements in the preceding point, it shall set aside supplemental special reserve based on the difference between the amount already set aside and other net deductions from shareholders' equity. For any subsequent reversal of other net deductions from shareholders' equity, the amount reversed may be distributed.

As of 1 January 2025 and 2024, special reserve set aside for the first-time adoption of TIFRS amounts to \$95,481 thousand. Furthermore, the Group has not reversed special reserve for the nine-month periods ended 30 September 2025 and 2024 as results of the no use, disposal or reclassification of related assets. As of 30 September 2025 and 2024, special reserve set aside for the first-time adoption of TIFRS amounts to \$95,481 thousand.

Details of the 2024 and 2023 earnings distribution and dividends per share as approved and resolved by the shareholders' meeting on 6 June 2025 and 14 June 2024, respectively, are as follows:

	Appropriation of earnings		Dividend per share (NT\$)	
	2024	2023	2024	2023
Legal reserve	\$818,601	\$530,198		
Special reserve	(842,353)	331,829		
Common stock -cash dividend	2,713,866	1,916,551	\$6.95	\$4.97

The shareholders' meeting on 6 June 2025 and 14 June 2024 resolved to distribute \$1,163,086 thousand and \$766,620 thousand from capital surplus to shareholders in the form of cash. Shareholders are entitled to receive \$2.98 and \$1.99 per share.

Please refer to Note 6.25 for further details on employees' compensation and remuneration to directors and supervisors.

D. Non-controlling interests

	For the nine-month periods ended September 30	
	2025	2024
Beginning balance	\$4,602,241	\$3,817,401
Profit attributable to non-controlling interests	1,141,006	677,023
Other comprehensive income, attributable to non-controlling interests, net of tax:		
Unrealized (losses) from equity instruments investments measured at fair value through other comprehensive income	—	(9,726)
Exchange differences resulting from translating the financial statements of a foreign operation	(156,109)	103,339
(Decreasing) in non-controlling interests	(455,897)	(313,429)
Ending balance	\$5,131,241	\$4,274,608

(22) Share-based payment

Certain employees of the Group are entitled to share-based payments as part of their remunerations. Services are provided by the employees in return for the equity instruments granted. These plans are accounted for as equity-settled share-based payments transactions.

A. Stock option plan for employees of the parent company

On July 7, 2022 and June 29, 2023, the Parent Company issue employee share options with a total number of 14,631 units and 2,058 units. Each unit entitles an optioned to subscribe for 1,000 shares of the Company's common shares. The exercise price of the option was set at the closing price of the Company's common share on the grant date. The optionee may exercise the options in accordance with certain schedules as prescribed by the plan starting 2 years from the grant date. Settlement upon the exercise of the options will be made through the issuance of new shares by the Parent Company.

The fair value of the share options is estimated at the grant date using a binomial option pricing-model, taking into account the terms and conditions upon which the share options were granted.

The contractual term of each option granted is 10 years. There are no cash settlement alternatives. The Group does not have a past practice of cash settlement for these employee share options.

The relevant details of the aforementioned share-based payments plan were as follows:

Date of grant	Total number of share options granted (in thousands)	The number of share that can be option each unit (share)	Exercise price of share Options (\$)(Note)
July 7, 2022	\$14,631	1,000	\$48.9
June 29, 2023	\$2,058	1,000	\$144.5

Note: The exercise prices are adjusted in accordance with the plan in the event that changes to the Company's total common shares occur or when the Company pays cash dividends

The following table lists the inputs to the model used for the plan granted during 2022 to 2023:

	June 29, 2023	July 7, 2022
Dividend yield(%)	—	—
Expected volatility(%)	40.36%	36.89%
Risk-free interest rate(%)	1.16%	1.2462%
Expected option life(year)	10 years	10 years
Option pricing model	Binomial option pricing model	Binomial option pricing model

The expected life of the share options is based on historical data and current expectations and is not necessarily indicative of exercise patterns that may occur. The expected volatility reflects the assumption that the historical volatility over a period similar to the life of the options is indicative of future trends, which may also not necessarily be the actual outcome.

The further details of the Group first three quarters of 2025 on the aforementioned share-based payments plan were as follows:

For the nine-month periods ended September 30				
Stock option	Number of share options outstanding	Average exercise price of share options (\$)	Fulfillment price range (\$)	Average remaining contract period of share options
Outstanding at beginning of period	12,242	\$49.4~146.1	—	
Granted	—	—	—	
Exercised	(3,017)	\$48.9~146.1	\$48.9~146.1	
Expired	(10)	—		
Outstanding at end of period	9,215	—		
Exercisable at end of period	9,215	—		6.76~7.74 years

The further details of the Group first three quarters of 2024 on the aforementioned share-based

payments plan were as follows:

For the nine-month periods ended September 30				
Stock option	Number of share options outstanding	Average exercise price of share options (\$)	Fulfillment price range (\$)	Average remaining contract period of share options
Outstanding at beginning of period	16,689	\$49.4~146.1	—	
Granted	—	—		
Exercised	(4,243)	\$49.4~50	\$49.4~50	
Expired	(62)	—		
Outstanding at end of period	12,384	—		
Exercisable at end of period	12,384	—		7.76~8.74 years

B. Expenses incurred on share-based payment transactions plan were shown as follows:

	For the nine-month periods ended September 30	
	2025	2024
Expenses incurred on share-based payment transactions (equity-settled share-based payments transactions)	\$160,788	\$277,521

C. No modification or cancellation of share-based payments plan has occurred for the years ended September 30 2025 and 2024.

(23) Operating revenues

A. Disaggregation of revenue

	For the three-month periods ended September 30		For the nine-month periods ended September 30	
	2025	2024	2025	2024
Sale of goods	\$38,936,900	\$19,064,683	\$91,864,360	\$50,857,226
Timing of revenue recognition:				
At a point in time	\$38,936,900	\$19,064,683	\$91,864,360	\$50,857,226

B. Contract balances

Contract liabilities - current

	30 Sep 2025	31 Dec 2024	30 Sep 2024
Sale of goods	\$2,132	\$2,881	\$2,909

During the period, contract liabilities significantly decreased as performance obligations are partially satisfied and \$2,881 thousand included in the contract liability balance at the beginning of the period was recognized as revenue during the period.

(24) Lease

A. Group as a lessee

The Group leases various properties, including real estate such as land and buildings, machinery and equipment and office equipment. The lease terms range from 1 to 50 years.

The Group's leases effect on the financial position, financial performance and cash flows are as follow:

(a) Amounts recognized in the balance sheet

I. Right-of-use assets

The carrying amount of right-of-use assets

	30 Sep 2025	31 Dec 2024	30 Sep 2024
Land	\$1,073,458	\$851,363	\$862,787
Buildings	1,949,691	2,136,333	2,040,783
Other equipment	18,058	32,302	18,529
Total	<u>\$3,041,207</u>	<u>\$3,019,998</u>	<u>\$2,922,099</u>

During the nine-month period ended 30 Sep 2025, the Group's additions to right-of-use assets amounted to \$405,614 thousand.

II. Lease liabilities

	30 Sep 2025	31 Dec 2024	30 Sep 2024
Current	\$368,637	\$335,637	\$273,899
Non-current	1,779,679	1,960,515	1,913,607
Total	<u>\$2,148,316</u>	<u>\$2,296,152</u>	<u>\$2,187,506</u>

Please refer to Note 6.26(4) for the interest on lease liabilities recognized during the nine-month period ended 30 Sep 2025 and refer to Note 12.5 Liquidity Risk Management for the maturity analysis for lease liabilities as of 30 Sep 2025.

(b) Amounts recognized in the statement of profit or loss

Depreciation charge for right-of-use assets

	For the three-month periods ended September 30		For the nine-month periods ended September 30	
	2025	2024	2025	2024
Land	\$7,542	\$6,322	\$19,758	\$15,662
Buildings	108,247	81,937	324,936	227,907
Other equipment	8,628	8,379	25,875	24,690
Total	<u>\$124,417</u>	<u>\$96,638</u>	<u>\$370,569</u>	<u>\$268,259</u>

(c) Income and costs relating to leasing activities

	For the three-month periods ended September 30		For the nine-month periods ended September 30	
	2025	2024	2025	2024
The expenses relating to short-term leases	<u>\$40,587</u>	<u>\$26,376</u>	<u>\$104,886</u>	<u>\$42,639</u>

(d) Cash outflow relating to leasing activities

During the nine-month period ended 30 September 2025, the Group's total cash outflows for leases amounting to \$396,122 thousand.

B. Group as a lessor (applicable to the disclosure requirement in IFRS 16)

Please refer to Note 6.11 for relevant disclosure of the Group's own occupied investment property. Leases of owned investment properties are classified as operating leases as they do not transfer substantially all the risks and rewards incidental to ownership of underlying assets.

	For the three-month periods ended September 30		For the nine-month periods ended September 30	
	2025	2024	2025	2024
Lease income for operating leases				
Income relating to fixed lease payments and variable lease payments that depend on an index or a rate	\$10,911	\$4,968	\$33,480	\$24,259

Please refer to Note 6.11 for relevant disclosure of property, plant and equipment for operating leases under IFRS 16. For operating leases entered by the Group, the undiscounted lease payments to be received and a total of the amounts for the remaining years as of 30 September 2025 are as follow:

	30 Sep 2025	31 Dec 2024	30 Sep 2025
Not later than one year	\$29,847	\$32,951	\$22,842
Later than one year and not later than five years	33,101	54,209	46,130
Later than five years	—	—	—
Total	\$62,948	\$87,160	\$68,972

(25) Summary statement of employee benefits, depreciation and amortization expenses by function:

Nature \ Function	For the three-month periods ended September 30					
	2025			2024		
	Operating costs	Operating expenses	Total amount	Operating costs	Operating expenses	Total amount
Employee benefits expense						
Salaries	\$2,731,358	\$1,069,858	\$3,801,216	\$1,832,040	\$614,828	\$2,446,868
Labor and health insurance	\$249,955	\$61,297	\$311,252	\$148,887	\$52,623	\$201,510
Pension	\$1,266	\$9,979	\$11,245	\$1,004	\$9,042	\$10,046
Other employee benefits expense	\$82,082	\$40,998	\$123,080	\$54,728	\$23,936	\$78,664
Depreciation	\$738,339	\$76,284	\$814,623	\$500,640	\$108,370	\$609,010
Amortization	\$2,775	\$13,025	\$15,800	\$2,536	\$17,178	\$19,714

Nature \ Function	For the nine-month periods ended September 30					
	2025			2024		
	Operating costs	Operating expenses	Total amount	Operating costs	Operating expenses	Total amount
Employee benefits expense						
Salaries	\$7,514,895	\$3,120,699	\$10,635,594	\$4,645,764	\$2,175,805	\$6,821,569
Labor and health insurance	\$673,514	\$182,720	\$856,234	\$366,615	\$146,741	\$513,356
Pension	\$3,497	\$29,276	\$32,773	\$2,814	\$26,575	\$29,389
Other employee benefits expense	\$209,009	\$102,183	\$311,192	\$125,026	\$65,173	\$190,199
Depreciation	\$2,009,044	\$280,764	\$2,289,808	\$1,424,711	\$293,646	\$1,718,357
Amortization	\$8,402	\$33,383	\$41,785	\$7,208	\$54,041	\$61,249

According to the Company's Articles of Incorporation, no less than 3% of profit of the current year is distributable as employees' compensation and no higher than 2% of profit of the current year is distributable as remuneration to directors and supervisors. However, the company's accumulated losses shall have been covered. The Company may, by a resolution adopted by a majority vote at a meeting of Board of Directors attended by two-thirds of the total number of directors, have the profit distributed as employees' compensation in the form of shares or in cash; and in addition thereto a report of such distribution is submitted to the shareholders' meeting. Information on the board of directors' resolution regarding the employees' compensation and remuneration to directors and supervisors can be obtained from the "Market Observation Post System" on the website of the TWSE.

Based on the profit of the current year, the Company estimated the amounts of the employees' compensation and remuneration to directors and supervisors for the three-month and nine-month periods ended 30 September 2025 to be \$216,075 thousand, \$104,553 thousand, \$513,942 thousand and \$248,682 thousand, respectively. The Company estimated the amounts of employees' compensation and remuneration to directors and supervisors for three-month and nine-month periods ended 30 September 2024 to be \$91,499 thousand, \$44,274 thousand, \$238,220 thousand and \$115,268 thousand, respectively. The aforementioned amounts were recognized as employee benefits expense. If the Board of Directors resolves to distribute employees' compensation in the form of stocks, the number of stocks distributed was calculated based on the closing price of the day before the Board of Directors meeting. The difference between the estimation and the resolution of the stockholder's meeting will be recognized in profit or loss in the subsequent year.

The Company's 2024 and 2023 employee compensation and director's compensation approved by the shareholders' meeting on 12 March 2025 and 13 March 2024 employee compensation and director's compensation reported by the shareholders' meeting of 12 March 2025 and 13 March 2024 are as follows:

	2024	2023
Employee compensation	\$320,000	\$215,000
Remuneration to directors and supervisors	157,000	104,296

The distribution was passed by the Board of Directors meeting held on 12 March, 2025 to distribute NT\$320,000 thousand and NT\$157,000 thousand in cash as employee compensation and remuneration to directors and supervisors of 2024, which has no material differences between the expense listed in the financial report of 2024.

No material differences exist between the estimated amount and the actual distribution of the employee compensation and remuneration to directors and supervisors for the year ended 31 December, 2024 and 2023.

(26) Non-operating income and expenses

A. Interest income

	For the three -month periods ended September 30		For the nine-month periods Ended September 30	
	2025	2024	2025	2024
Interest income from bank deposits	\$135,437	\$126,004	\$410,133	\$365,544
Financial assets at amortized cost	1,002	1,250	10,991	10,610
Others	14	11	40	36
Total	\$136,453	\$127,265	\$421,164	\$376,190

B. Other income

	For the three -month periods ended September 30		For the nine-month periods Ended Septembe30	
	2025	2024	2025	2024
Rental income	\$10,911	\$4,968	\$33,480	\$24,259
Others	167,208	375,053	638,019	1,005,620
Total	<u>\$178,119</u>	<u>\$380,021</u>	<u>\$671,499</u>	<u>\$1,029,879</u>

C. Other gains and losses

	For the three-month periods ended September 30		For the nine-month periods Ended Septembe 30	
	2025	2024	2025	2024
(Losses) on disposal of property, plant and equipment	(\$64,581)	(\$44,054)	(\$104,691)	(\$107,426)
Gain on disposal of investments, net	6,881	—	10,601	—
Foreign exchange income, net	49,336	(10,622)	808,260	213,980
Impairment loss	1,681	(38,437)	(52,222)	(38,437)
Others	(6,753)	(11,550)	(23,404)	(33,457)
Total	<u>(\$13,436)</u>	<u>(\$104,663)</u>	<u>\$638,544</u>	<u>\$34,660</u>

D. Finance costs

	For the three-month periods ended September 30		For the nine-month periods ended September 30	
	2025	2024	2025	2024
Interest on borrowings from bank	\$134,268	\$93,273	\$376,883	\$273,610
Interest on corporate bonds payable	2,080	3,720	9,520	11,160
Interest on lease liabilities	14,919	12,091	47,113	31,140
Total	<u>\$151,267</u>	<u>\$109,084</u>	<u>\$433,516</u>	<u>\$315,910</u>

(27) Components of other comprehensive income

For the three-month period ended 30 September 2025:

	Arising during the period	Reclassification adjustments during the period	Other comprehensive income, before tax	Income tax relating to components of other comprehensive income	Other comprehensive income, net of tax
Not to be reclassified to profit or loss in subsequent periods:					
Unrealized gain from equity instruments investments measured at fair value through other comprehensive income	\$91,931	—	\$91,931	—	\$91,931
To be reclassified to profit or loss in subsequent periods:					
Exchange differences resulting from translating the financial statements of a foreign operation	1,365,853	—	1,365,853	(\$37,772)	1,328,081
Share of other comprehensive income of associates accounted for using the equity method	5,853	—	5,853	—	5,853
Total of other comprehensive income	<u>\$1,463,637</u>	<u>—</u>	<u>\$1,463,637</u>	<u>(\$37,772)</u>	<u>\$1,425,865</u>

For the nine-month period ended 30 September 2025:

	Arising during the period	Reclassification adjustments during the period	Other comprehensive income, before tax	Income tax relating to components of other comprehensive income	Other comprehensive income, net of tax
Not to be reclassified to profit or loss in subsequent periods:					
Unrealized gain from equity instruments investments measured at fair value through other comprehensive income	(\$17,550)	—	(\$17,550)	—	(\$17,550)
To be reclassified to profit or loss in subsequent periods:					
Exchange differences resulting from translating the financial statements of a foreign operation	(1,771,504)	—	(1,771,504)	\$167,788	(1,603,716)
Share of other comprehensive income of associates accounted for using the equity method	12,021	—	12,021	—	12,021
Total of other comprehensive income	(\$1,777,033)	—	(\$1,777,033)	\$167,788	(\$1,609,245)

For the three-month period ended 30 September 2024:

	Arising during the period	Reclassification adjustments during the period	Other comprehensive income, before tax	Income tax relating to components of other comprehensive income	Other comprehensive income, net of tax
Not to be reclassified to profit or loss in subsequent periods:					
Unrealized losses from equity instruments investments measured at fair value through other comprehensive income	(\$93,348)	—	(\$93,348)	—	(\$93,348)
To be reclassified to profit or loss in subsequent periods:					
Exchange differences resulting from translating the financial statements of a foreign operation	415,769	—	415,769	(94,251)	321,518
Share of other comprehensive income of associates accounted for using the equity method	9,410	—	9,410	—	9,410
Total of other comprehensive income	\$331,831	—	\$331,831	(\$94,251)	\$237,580

For the nine-month period ended 30 September 2024:

	Arising during the period	Reclassification adjustments during the period	Other comprehensive income, before tax	Income tax relating to components of other comprehensive income	Other comprehensive income, net of tax
Not to be reclassified to profit or loss in subsequent periods:					
Unrealized gain from equity instruments investments measured at fair value through other comprehensive income	\$246,750	—	\$246,750	—	\$246,750
To be reclassified to profit or loss in subsequent periods:					
Exchange differences resulting from translating the financial statements of a foreign operation	1,026,073	—	1,026,073	(\$208,872)	817,201
Share of other comprehensive income of associates accounted for using the equity method	4,232	—	4,232	—	4,232
Total of other comprehensive income	<u>\$1,277,055</u>	<u>—</u>	<u>\$1,277,055</u>	<u>(\$208,872)</u>	<u>\$1,068,183</u>

(28) Income tax

A. The major components of income tax expense are as follows:

Income tax expense recognized in profit or loss

	For the three-month periods ended September 30		For the nine-month periods ended September 30	
	2025	2024	2025	2024
Current income tax expense:				
Current income tax charge	\$2,868,866	\$952,843	\$5,153,384	\$2,230,717
Current tax expense related to Pillar Two legislation	61,976	41,547	163,436	58,877
Deferred tax expense :				
Deferred tax expense relating to origination and reversal of temporary differences	(623,419)	(168,107)	(274,827)	(108,976)
Total income tax expense	<u>\$2,307,423</u>	<u>\$826,283</u>	<u>\$5,041,993</u>	<u>\$2,180,618</u>

B. Income tax relating to components of other comprehensive income

	For the three-month periods ended September 30		For the nine-month periods ended September 30	
	2025	2024	2025	2024
Deferred tax expense:				
Exchange differences resulting from translating the financial statements of foreign operations	\$37,772	\$94,251	(\$167,788)	\$208,872
Income tax relating to components of other comprehensive income	<u>\$37,772</u>	<u>\$94,251</u>	<u>(\$167,788)</u>	<u>\$208,872</u>

C. The assessment of income tax returns

The Company's income tax returns through 2022 have been assessed and approved by the Tax Authority.

(29) Earnings per share

	For the nine-month period ended September 30 2025		
	Amount	Number of shares (shares in thousands)	Earnings per share
Basic earnings per share Profit attributable to ordinary equity holders of the Company (in thousand NT\$)	\$12,550,451	\$389,156	\$32.25
Assumed conversion of all dilutive potential ordinary shares			
Employees' compensation	—	524	
Employee share options	—	8,206	
Diluted earnings per share Profit attributable to ordinary equity holders of the Company (in thousand NT\$)	\$12,550,451	397,886	\$31.54
For the nine-month period ended September 30 2024			
	Number of shares		
	Amount	(shares in thousands)	Earnings per share
Basic earnings per share Profit attributable to ordinary equity holders of the Company (in thousand NT\$)	\$5,834,782	\$384,373	\$15.18
Assumed conversion of all dilutive potential ordinary shares			
Employees' compensation	—	404	
Employee share options	—	10,388	
Diluted earnings per share Profit attributable to ordinary equity holders of the Company (in thousand NT\$)	\$5,834,782	395,165	\$14.77
For the three-month period ended September 30 2025			
	Number of shares		
	Amount	(shares in thousands)	Earnings per share
Basic earnings per share Profit attributable to ordinary equity holders of the Company (in thousand NT\$)	\$5,339,300	\$390,524	\$13.67
Assumed conversion of all dilutive potential ordinary shares			
Employees' compensation	—	123	
Employee share options	—	5,973	
Diluted earnings per share Profit attributable to ordinary equity holders of the Company (in thousand NT\$)	\$5,339,300	396,620	\$13.46

For the three-month period ended September 30 2024			
	Amount	Number of shares	Earnings per share
		(shares in thousands)	
Basic earnings per share			
Profit attributable to ordinary equity holders of the Company (in thousand NT\$)	\$2,323,510	385,965	\$6.02
Assumed conversion of all dilutive potential ordinary shares			
Employees' compensation	—	212	
Employee share options	—	5,646	
Diluted earnings per share			
Profit attributable to ordinary equity holders of the Company (in thousand NT\$)	\$2,323,510	391,823	\$5.93

7. Related party transactions

Information of the related parties that had transactions with the Group during the financial reporting period is as follows:

Related parties and relationship

Name of related parties	Relationship with the Group
ASIA VITAL COMPONENTS Educational Foundation	Substantive related party

Significant transactions with the related parties

(1) Charitable contributions

	For the three-month periods ended September 30		For the nine-month periods ended September 30	
	2025	2024	2025	2024
Other related parties				
ASIAVITALCOMPONENTS Educational Foundation	—	—	\$70,862	—

(2) Key management personnel compensation

	For the three-month periods ended September 30		For the nine-month periods ended September 30	
	2025	2024	2025	2024
Short-term employee benefits	\$17,077	\$33,010	\$35,707	\$54,597
Post-employment benefits	578	274	885	885
Share-based payments	—	—	17,149	29,600
Total	\$17,655	\$33,284	\$53,741	\$85,082

8. Assets pledged as security

The following table lists assets of the Group pledged as security:

Assets pledged for security	Carrying amount		
	30 Sep 2025	31 Dec 2024	30 Sep 2024
Financial assets measured at amortized cost	\$3,430,117	\$2,075,672	\$1,979,710
Land	88,235	88,235	88,235
Buildings	76,716	106,714	112,968
Investment property	54,932	29,021	24,130
Refundable deposits	8,500	8,500	3,500
Total	<u>\$3,658,500</u>	<u>\$2,308,142</u>	<u>\$2,208,543</u>

9. Commitments and contingencies

(1) Legal claim contingency

None.

(2) The Group signed the contract of the new plant and land-use-right in Vietnam, AVC OPTICS (WUHAN) CORP and AVC VITAL COMPONENTS(DONGGUAN) CO.,LTD. for opreating purpose, and 1,736 million dollars not paid until 30 September 2025.

(3) Other

The Group guaranteed a deposit for customs in the amount of \$2,500 thousand and \$6,000 thousand from Bank of Taiwan and Taiwan Cooperative Bank, respectively.

10. Losses due to major disasters

None.

11. Significant subsequent events

None.

12. Financial instruments

(1) Categories of financial instruments

Financial assets

	30 Sep 2025	31 Dec 2024	30 Sep 2024
Financial assets at fair value through profit or loss:			
Financial assets at fair value through other comprehensive income	\$473,298	\$493,663	\$484,196
Financial assets measured at amortized cost			
Cash and cash equivalents (excluding cash on hand)	43,765,793	29,912,550	29,996,857
Financial assets measured at amortized cost	3,460,501	2,108,391	2,011,296
Amounts receivables	9,827,564	8,306,448	6,977,389
Subtotal	<u>\$57,053,858</u>	<u>\$40,327,389</u>	<u>\$38,985,542</u>
Total	<u>\$57,527,156</u>	<u>\$40,821,052</u>	<u>\$39,469,738</u>

Financial liabilities

	30 Sep 2025	31 Dec 2024	30 Sep 2024
Financial liabilities at amortized cost:			
Short-term loans	\$14,798,554	\$9,585,252	\$8,250,973
Short-Term Notes and Bills Payable	—	—	70,000
Amounts payables	57,081,711	36,808,568	31,760,713
Corporate bonds payable (including current portion)	—	2,400,000	2,400,000
Lease liabilities (including current portion)	6,887,042	4,493,416	3,888,093
Long-term loans (including current portion)	2,148,316	2,296,152	2,187,506
Total	<u>\$80,915,623</u>	<u>\$55,583,388</u>	<u>\$48,557,285</u>

(2) Financial risk management objectives and policies

The Group's principal financial risk management objective is to manage the market risk, credit risk and liquidity risk related to its operating activities. The Group identifies measures and manages the aforementioned risks based on the Group's policy and risk appetite.

The Group has established appropriate policies, procedures and internal controls for financial risk management. Before entering into significant transactions, due approval process by the Board of Directors must be carried out based on related protocols and internal control procedures. The Group complies with its financial risk management policies at all times.

(3) Market risk

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of the changes in market prices. Market prices comprise currency risk, interest rate risk and other price risk (such as equity risk).

In practice, it is rarely the case that a single risk variable will change independently from other risk variable, there is usually interdependencies between risk variables. However the sensitivity analysis disclosed below does not take into account the interdependencies between risk variables.

A. Foreign currency risk

The Group's exposure to the risk of changes in foreign exchange rates relates primarily to the Group's operating activities (when revenue or expense are denominated in a different currency from the Group's functional currency) and the Group's net investments in foreign subsidiaries. The Group has certain foreign currency receivables to be denominated in the same foreign currency with certain foreign currency payables, therefore forming a natural hedge. Furthermore, as net investments in foreign subsidiaries are for strategic purposes, they are not hedged by the Group.

The foreign currency sensitivity analysis of the possible change in foreign exchange rates on the Group's profit is performed on significant monetary items denominated in foreign currencies as at the end of the reporting period. The Group's foreign currency risk is mainly related to the volatility in the exchange rates for USD and RMB. The information of the sensitivity analysis is as follows:

- (a) When NTD strengthens/weakens against USD by 1%, the profit for the nine-month periods ended 30 September 2025 and 2024 is increased or decreased by \$186,871 thousand and by \$33,818 thousand, respectively.
- (b) When NTD strengthens/weakens against RMB by 1%, the profit for the nine-month periods ended 30 September 2025 and 2024 is increased or decreased by \$92,411 thousand and by \$12,939 thousand, respectively.

B. Interest rate risk

Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Group's exposure to the risk of changes in market interest rates relates primarily to bank borrowings with fixed interest rates and variable interest rates.

The Group manages its interest rate risk by having a balanced portfolio of fixed and variable loans and borrowings and entering into interest rate swaps. Hedge accounting does not apply to these swaps as they do not qualify for it.

The interest rate sensitivity analysis is performed on items exposed to interest rate risk as at the end of the reporting period. A change of 10 basis points of interest rate in a reporting period could cause the profit for the nine-month periods ended 30 September 2025 and 2024 to decrease/increase by \$25,901 thousand and \$17,623 thousand, respectively.

C. Equity price risk

The fair value of the Group's unlisted equity securities are susceptible to market price risk arising from uncertainties about future values of the investment securities. The Group's unlisted equity securities are classified as financial assets at fair value through other comprehensive income.

The equity price sensitivity analysis is based on fair value changes as at the end of the reporting period. For the nine-month periods ended 30 September 2025 and 2024, a change of 5% in the price classified as equity instruments investments measured at fair value through other comprehensive income could cause the other comprehensive income to increase/ decrease by \$23,665 thousand and \$24,210 thousand, respectively.

Please refer to Note 12.8 for sensitivity analysis information of other equity instruments or derivatives that are linked to such equity instruments whose fair value measurement is categorized under Level 3.

(4) Credit risk management

Credit risk is the risk that a counterparty will not meet its obligations under a contract, leading to a financial loss. The Group is exposed to credit risk from operating activities (primarily for accounts receivables and notes receivables) and from its financing activities, including bank deposits and other financial instruments.

Credit risk is managed by each business unit subject to the Group's established policy, procedures and control relating to credit risk management. Credit limits are established for all counter parties based on their financial position, rating from credit rating agencies, historical experience, prevailing economic condition and the Group's internal rating criteria etc. Certain counter parties' credit risk will also be managed by taking credit enhancing procedures, such as requesting for prepayment or insurance.

As of 30 September 2025, 31 December 2024 and 30 September 2024, amounts receivables from top ten customers represent 88.14%, 77.30% and 64.50% of the total accounts receivables of the Group, respectively. The credit concentration risk of other accounts receivables is insignificant.

Credit risk from balances with banks, fixed income securities and other financial instruments is managed by the Group's treasury in accordance with the Group's policy. The Group only transacts with counterparties approved by the internal control procedures, which are banks and financial institutions, companies and government entities with good credit rating. Consequently, there is no significant credit risk for these counter parties.

(5) Liquidity risk management

The Group's objective is to maintain a balance between continuity of funding and flexibility through the use of cash and cash equivalents and bank borrowings. The table below summarizes the maturity profile of the Group's financial liabilities based on the contractual undiscounted payments and contractual maturity. The payment amount includes the contractual interest. The undiscounted payment relating to borrowings with variable interest rates is extrapolated based on the estimated interest rate yield curve as of the end of the reporting period.

Non-derivative financial liabilities

	< 1 year	2 to 3 years	4 to 5 years	> 5 years	Total
As of 30 September 2025					
Loans	\$16,402,660	\$2,548,689	\$2,996,411	\$75,059	\$22,022,819
Corporate bonds payable	\$57,026,121	—	—	—	\$57,026,121
Lease liabilities	\$422,292	\$613,327	\$519,022	\$826,961	\$2,381,602
As of 31 December 2024					
Loans	\$10,992,356	\$2,542,509	\$754,138	\$151,455	\$14,440,458
Corporate bonds payable	\$2,414,880	—	—	—	\$2,414,880
Amounts payables	\$36,760,755	—	—	—	\$36,760,755
Lease liabilities	\$424,454	\$617,265	\$543,966	\$1,073,367	\$2,659,052
As of 30 September 2024					
Loans	\$9,799,844	\$2,184,421	\$422,229	—	\$12,406,494
Short-term note payables	\$70,090	—	—	—	\$70,090
Corporate bonds payable	\$2,414,880	—	—	—	\$2,414,880
Amounts payables	\$31,726,526	—	—	—	\$31,726,526
Lease liabilities	\$339,455	\$513,771	\$537,681	\$1,151,935	\$2,542,842

(6) Reconciliation of liabilities arising from financing activities

Reconciliation of liabilities for the nine-month period ended 30 September 2025:

	Short-term borrowings	Corporate bonds payable	Long-term borrowings	Lease liabilities
As at 1 Jan 2025	\$9,585,252	\$2,400,000	\$4,493,416	\$2,296,152
Cash flows	5,840,662	(2,400,000)	2,434,437	(291,236)
Non-cash changes	(627,360)	—	(40,811)	143,400
As at 30 Sep 2025	<u>\$14,798,554</u>	<u>—</u>	<u>\$6,887,042</u>	<u>\$2,148,316</u>

	Guarantee Deposits	Total liabilities from financing activities
As at 1 Jan 2025	\$38,659	\$18,813,479
Cash flows	(1,386)	5,582,477
Non-cash changes	—	(524,771)
As at 30 Sep 2025	<u>\$37,273</u>	<u>\$23,871,185</u>

Reconciliation of liabilities for the nine-month period ended 30 September 2024:

	Short-term borrowings	Short-term note payables	Corporate bonds payable	Long-term borrowings	Lease liabilities
As at 1 Jan 2024	\$6,765,540	\$30,000	\$2,400,000	\$3,764,150	\$1,123,480
Cash flows	1,432,819	40,000	—	114,694	(231,762)
Non-cash changes	52,614	—	—	9,249	1,295,788
As at 30 Sep 2024	<u>\$8,250,973</u>	<u>\$70,000</u>	<u>\$2,400,000</u>	<u>\$3,888,093</u>	<u>\$2,187,506</u>

	Guarantee Deposits	Total liabilities from financing activities
As at 1 Jan 2024	\$35,503	\$14,118,673
Cash flows	2,782	1,358,533
Non-cash changes	—	1,357,651
As at 30 Sep 2024	<u>\$38,285</u>	<u>\$16,834,857</u>

(7) Fair values of financial instruments

A. The methods and assumptions applied in determining the fair value of financial instruments:

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The following methods and assumptions were used by the Group to measure or disclose the fair values of financial assets and financial liabilities:

- The carrying amount of cash and cash equivalents, accounts receivables, accounts payable and other current liabilities approximate their fair value due to their short maturities.
- Fair value of equity instruments without market quotations (including private placement of listed equity securities, unquoted public company and private company equity securities) are estimated using the market method valuation techniques based on parameters such as prices based on market transactions of equity instruments of identical or comparable entities and other relevant information (for example, inputs such as discount for lack of marketability, P/E ratio of similar entities and Price-Book ratio of similar entities).

B. Fair value of financial instruments measured at amortized cost

The carrying amount of financial assets and financial liabilities measured at amortized cost approximate their fair value due to their short maturities.

C. Fair value measurement hierarchy for financial instruments

Please refer to Note 12.8 for fair value measurement hierarchy for financial instruments of the Group.

(8) Fair value measurement hierarchy

A. Fair value measurement hierarchy

All asset and liabilities for which fair value is measured or disclosed in the financial statements are categorized within the fair value hierarchy, based on the lowest level input that is significant to the fair value measurement as a whole. Level 1, 2 and 3 inputs are described as follows:

Level 1 – Quoted (unadjusted) market prices in active markets for identical assets or liabilities that the entity can access at the measurement date

Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly

Level 3 – Unobservable inputs for the asset or liability

For assets and liabilities that are recognized in the financial statements on a recurring basis, the Group determines whether transfers have occurred between Levels in the hierarchy by re-assessing categorization at the end of each reporting period.

B. Fair value measurement hierarchy of the Group's assets and liabilities

The Group does not have assets that are measured at fair value on a non-recurring basis. Fair value measurement hierarchy of the Group's assets and liabilities measured at fair value on a recurring basis is as follows:

As at 30 September 2025

	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Financial assets:				
Financial assets at fair value through other comprehensive income				
Equity instrument measured at fair value through other comprehensive income	\$318,987	—	\$154,311	\$473,298

As at 31 December 2024

	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Financial assets:				
Financial assets at fair value through other comprehensive income				
Equity instrument measured at fair value through other comprehensive income	\$368,257	—	\$125,406	\$493,663

As at 30 September 2024

	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Financial assets:				
Financial assets at fair value through other comprehensive income				
Equity instrument measured at fair value through other comprehensive income	\$359,227	—	\$124,969	\$484,196

C. Reconciliation for fair value measurements in Level 3 is as follows:

	Financial assets at fair value through other comprehensive income
As at 1 Jan 2025	\$125,406
Unrealized income from equity instruments investments measured at fair value through other comprehensive income	31,720
Other	(2,815)
As at 30 Sep 2025	\$154,311

	Financial assets at fair value through other comprehensive income
As at 1 Jan 2024	\$164,310
Unrealized income from equity instruments investments measured at fair value through other comprehensive income	(8,596)
Transfer-out from Level 3	(31,881)
Other	1,136
As at 30 Sep 2024	\$124,969

D. Information on significant unobservable inputs of fair value measurement in Level 3 fair value hierarchy:

Significant unobservable inputs of fair value measurement in Level 3 fair value hierarchy are as follows :

As at 30 Sep 2025:

	Valuation techniques	Significant unobservable inputs	Quantitative information	Correlation between inputs and fair value	Sensitivity Analysis of correlation between inputs and fair value
Financial assets: Financial assets at fair value through other comprehensive income stocks	Market approach and net asset approach	Discount for lack of marketability	25.7%	The greater degree of lack of marketability, the lower the estimated fair value is determined.	1% strengthens (weakens) in the discount for lack of marketability would result in (decreased) increased in the Group's profit or loss by \$474 thousand.

As at 31 December 2024:

	Valuation techniques	Significant unobservable inputs	Quantitative information	Correlation between inputs and fair value	Sensitivity Analysis of correlation between inputs and fair value
Financial assets:					
Financial assets at fair value through other comprehensive income					
stocks	Market approach and net asset approach	Discount for lack of marketability	35%	The greater degree of lack of marketability, the lower the estimated fair value is determined.	1% strengthens (weakens) in the discount for lack of marketability would result in (decreased) increased in the Group's profit or loss by \$563 thousand.

As at 30 Sep 2024:

	Valuation techniques	Significant unobservable inputs	Quantitative information	Correlation between inputs and fair value	Sensitivity Analysis of correlation between inputs and fair value
Financial assets:					
Financial assets at fair value through other comprehensive income					
stocks	Market approach and net asset approach	Discount for lack of marketability	35%	The greater degree of lack of marketability, the lower the estimated fair value is determined.	1% strengthens (weakens) in the discount for lack of marketability would result in (decreased) increased in the Group's profit or loss by \$563 thousand.

(9) Significant assets and liabilities denominated in foreign currencies

Information regarding the significant assets and liabilities denominated in foreign currencies is listed below:

30 September 2025			
	Foreign currencies (in thousands)	Foreign exchange rate	NT\$ (in thousands)
Financial assets			
Monetary items:			
USD	\$1,284,142	30.4450	\$39,095,704
RMB	\$4,671,809	4.2714	\$19,955,163
Financial liabilities			
Monetary items:			
USD	\$670,345	30.4450	\$20,408,640
RMB	\$6,835,289	4.2714	\$29,196,255

31 December 2024			
	Foreign currencies (in thousands)	Foreign exchange rate	NT\$ (in thousands)
<u>Financial assets</u>			
Monetary items:			
USD	\$629,985	32.7850	\$20,654,047
RMB	\$3,829,593	4.4780	\$17,148,919
<u>Financial liabilities</u>			
Monetary items:			
USD	\$290,440	32.7850	\$9,522,089
RMB	\$5,130,990	4.4780	\$22,976,575
30 September 2024			
	Foreign currencies (in thousands)	Foreign exchange rate	NT\$ (in thousands)
<u>Financial assets</u>			
Monetary items:			
USD	\$601,117	31.6500	\$19,025,359
RMB	\$3,962,847	4.5230	\$17,923,956
<u>Financial liabilities</u>			
Monetary items:			
USD	\$494,269	31.6500	\$15,643,609
RMB	\$4,248,915	4.5230	\$19,217,842

The Group's functional currency are various, and hence is not able to disclose the information of exchange gains and losses by each significant assets and liabilities denominated in foreign currencies. The foreign exchange gain was \$808,260 thousand and \$213,980 thousand for the nine-month periods ended 30 September 2025 and 2024, respectively.

(10) Capital management

The primary objective of the Group's capital management is to ensure that it maintains a strong credit rating and healthy capital ratios in order to support its business and maximize shareholder value. The Group manages its capital structure and makes adjustments to it, in light of changes in economic conditions. To maintain or adjust the capital structure, the Group may adjust dividend payment to shareholders, returning capital to shareholders or issuing new shares.

13. Other disclosure

(1) Information at significant transactions and on investees

- A. Financing provided to others for the nine-month periods ended 30 September 2025: Please refer to Attachment 1.
- B. Endorsement/Guarantee provided to others for the nine-month periods ended 30 September 2025: Please refer to Attachment 2.
- C. Securities held as of 30 September 2025: Please refer to Attachment 3.

- D. Related party transactions for purchases and sales amounts exceeding the lower of NT\$100 million or 20% of the capital stock for the nine-month periods ended 30 September 2025: Please refer to Attachment 4.
- E. Receivables from related parties with amounts exceeding the lower of NT\$100 million or 20% of capital stock as of 30 September 2025: Please refer to Attachment 5.
- F. Direct or indirect significant influence or control over the investees for the nine-month periods ended 30 September 2025 (excluding investments in China): Please refer to Attachment 6.
- G. Others: Significant inter-company transactions during the reporting periods: Please refer to Attachment 8.

(2) Information on investments in mainland China

- A. Information on investments in mainland China: Please refer to Attachment 7.
- B. Significant transactions conducted between January 1 and September 30, 2025, with the investee companies in China directly or indirectly through the third area and the relevant prices, payment terms and unrealized gains and losses:
 - (a) Purchase, ending balance of related payables and their weightings: Please refer to Attachment 4.
 - (b) Sales, the ending balance of related receivables and their weightings: Please refer to Attachment 4.
 - (c) Ending balance of endorsements/guarantees or collateral provided and the purposes: Please refer to Attachment 2.
 - (d) Transactions that have significant impact on the profit or loss of current period or the financial position: None.

14. Segment information

For management purposes, the Group is organized into business units based on their products and services and has two reportable operating segments as follows:

(1) General management segment:

The general management segment is responsible for the Group's operation planning and owns manufacturing, R&D and sales functions.

(2) Overseas segment:

The overseas segment owns manufacturing and sales functions.

No operating segments have been aggregated to form the above reportable operating segments.

Management monitors the operating results of its business units separately for the purpose of making decisions about resource allocation and performance assessment.

Segment performance is evaluated based on operating profit or loss and is measured based on accounting policies consistent with those in the consolidated financial statements.

However, finance costs, financial benefits and income taxes are managed on a group basis and are not allocated to operating segments.

Transfer prices between operating segment are on an arm's length basis in a manner similar to transactions with third parties.

For the three-month period ended 30 September 2025

	Overseas	General management	Adjustment and elimination	Total
Revenue				
External customer	\$5,932,230	\$33,004,670	—	\$38,936,900
Inter-segment (Note)	38,157,244	1,400,437	(\$39,557,681)	—
Total revenue	\$44,089,474	\$34,405,107	(\$39,557,681)	\$38,936,900
Segment profit	\$3,936,040	\$4,299,134	(\$18,226)	\$8,216,948

Note: Inter-segment revenues were eliminated on consolidation.

For the three-month period ended 30 September 2024

	Overseas	General management	Adjustment and elimination	Total
Revenue				
External customer	\$5,558,420	\$13,506,263	—	\$19,064,683
Inter-segment (Note)	15,948,156	1,136,860	(\$17,085,016)	—
Total revenue	\$21,506,576	\$14,643,123	(\$17,085,016)	\$19,064,683
Segment profit	\$1,350,431	\$2,025,482	\$51,667	\$3,427,580

Note: Inter-segment revenues were eliminated on consolidation.

For the nine-month period ended 30 September 2025

	Overseas	General management	Adjustment and elimination	Total
Revenue				
External customer	\$17,837,293	\$74,027,067	—	\$91,864,360
Inter-segment (Note)	85,556,684	3,813,942	(\$89,370,626)	—
Total revenue	\$103,393,977	\$77,841,009	(\$89,370,626)	\$91,864,360
Segment profit	\$8,165,172	\$10,673,276	(\$104,998)	\$18,733,450

Note: Inter-segment revenues were eliminated on consolidation.

For the nine-month period ended 30 September 2024

	Overseas	General management	Adjustment and elimination	Total
Revenue				
External customer	\$14,993,159	\$35,864,067	—	\$50,857,226
Inter-segment (Note)	40,497,520	2,768,257	(\$43,265,777)	—
Total revenue	\$55,490,679	\$38,632,324	(\$43,265,777)	\$50,857,226
Segment profit	\$4,101,279	\$4,493,309	\$97,835	\$8,692,423

Note: Inter-segment revenues were eliminated on consolidation.

As of 30 September 2025, 31 December 2024 and 30 September 2024, the assets of reportable segment information were as follows:

	Overseas	General management	Adjustment and elimination	Total
30 September 2025 Assets	\$109,984,708	\$74,352,672	(\$45,083,338)	\$139,254,042
31 December 2024 Assets	\$78,122,000	\$46,102,974	(\$24,319,413)	\$99,905,561
30 September 2024 Assets	\$69,879,112	\$39,072,515	(\$20,851,632)	\$88,099,995

ASIA VITAL COMPONENTS CO., LTD AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE-MONTH PERIOD ENDED SEPTEMBER 30, 2025
(Expressed in thousands of New Taiwan Dollars unless Otherwise Specified)
FINANCING PROVIDED TO OTHERS

TABLE 1

No (Note 1)	Financing Company	Counter-party	Financial Statement Account (Note 2)	Related Party	Maximum Balance for the Period (Note 3)	Ending Balance (Note 8)	Amount Actually Drawn	Interest Rate	Accumulated Outflow of Investment from Taiwan as of Sep 30, 2025 (Note 4)	Transaction Amounts (Note 5)	Reason for Financing (Note 6)	Allowance for Doubtful Accounts	Collateral		Financing Limits for Each Borrower	Financing Company's Total Financing Amount Limits	Note
													Item	Value			
1	MACE TECH CORP.	WUCHIDA INTERNATIONAL CO., LTD.	Other receivables	Yes	\$106,558 (USD3,500 thousand)	\$106,558 (USD3,500 thousand)	\$106,558 (USD3,500 thousand)	0.00%	2	—	Operating capital	—	—	—	\$2,134,330	\$2,134,330	(Note 7)
2	CHIHUNG INTERNATIONAL LTD.	JADS CORPORATION (HK) LIMITED	Other receivables	Yes	\$152,225 (USD5,000 thousand)	\$152,225 (USD5,000 thousand)	\$152,225 (USD5,000 thousand)	0.00%	2	—	Operating capital	—	—	—	\$2,991,279	\$2,991,279	(Note 7)
3	ASIA VITAL COMPONENTS (CHINA) CO., LTD.	AVC OPTICS (WUHAN) CORP.	Other receivables	Yes	\$2,135,502 (CNY500,000 thousand)	\$2,135,502 (CNY500,000 thousand)	\$1,708,402 (CNY400,000 thousand)	3.00%	2	—	Operating capital	—	—	—	\$2,879,502	\$2,879,502	(Note 7)

Note 1 : Companies are coded as follows :

(1) ASIA VITAL COMPONENTS Co., LTD. is coded "0".

(2) The investees are coded from "1" in the order presented in the table above.

Note 2 : Receivables from affiliates and related parties, shareholder transactions, prepayments and temporary payments etc. are required to be disclosed in this field if they are financings provided to others.

Note 3 : The maximum balance of financing provided to others for the three-month ended March 31, 2025.

Note 4 : Nature of Financing are coded as follows :

(1) Business transaction is coded "1".

(2) Short-term financing is coded "2".

Note 5 : If nature of financing is business transaction, the amount of transaction should be disclosed.

Note 6 : With respect to short-term financing, the reasons of financing and the purpose of use by the counter-party shall be specified, such as loan repayment, equipment acquisition or operating capital.

Note 7 : The financing provided to any single entity shall not exceed 40% of the net worth. Total financing shall not exceed 40% of the net worth.

Note 8 : If public companies, pursuant to Paragraph 1, Article 14 of Regulations Governing Lending of Funds and Making of Endorsements / Guarantees by Public Companies, resolve each individual lending at the board meetings, the amounts resolved (before any drawing) shall be the publicly-announced balance to disclose the risk they assume; provided however, if any repayment is made subsequently, the outstanding balance after such repayment shall be disclosed to reflect the risk adjusted. If public companies, pursuant to Paragraph 2, Article 14 of the same Regulations, authorize the chairperson by board resolution, within a certain monetary limit and a period not to exceed one year,

to give loans in instalments or to make a revolving credit line available, the amount resolved shall be the publicly-announced balance. Although repayment may be made subsequently, as drawings are likely to happen, the amount of financing resolved by the board shall be recorded as the publicly-announced balance.

Note 9 : All the above transactions were eliminated on consolidation.

ASIA VITAL COMPONENTS CO., LTD AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE-MONTH PERIOD ENDED SEPTEMBER 30, 2025
(Expressed in thousands of New Taiwan Dollars unless Otherwise Specified)
ENDORSEMENT/GUARANTEE PROVIDED TO OTHERS

TABLE 2

No (Note 1)	Endorsement/Guarantee Provider	Guaranteed Party		Limits on Endorsement/Guarantee Amount Provided to Each Guaranteed Party (Note 3&4)	Maximum Balance for the Period (Note 11)	Ending Balance (Note 12)	Amount Actually Drawn (Note 13)	Amount of Endorsement/ Guarantee secured by Properties	Accumulated Outflow of Investment from Taiwan as of Sep 30, 2025	Maximum Endorsement/ Guarantee Amount Allowed (Note 3&4)	Endorsement provided by parent company to subsidiaries (Note 14)	Endorsement provided by subsidiaries to parent company (Note 14)	Carrying Amount as of Sep 30, 2025 (Note 14)	Note
		Name	Nature of Relationship (Note 2)											
0	ASIA VITAL COMPONENTS CO.,LTD	AVC PRECISION, CO., LTD.	2	\$36,460,751	\$427,100 (CNY100,000 thousand)	\$427,100 (CNY100,000 thousand)	\$232,920 (CNY54,535 thousand)	—	1.17%	\$54,691,127	Y	N	Y	(Note 3)
0	ASIA VITAL COMPONENTS CO.,LTD	ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD.	2	\$36,460,751	\$2,101,575 (USD55,000 thousand) (CNY100,000 thousand)	\$2,101,575 (USD55,000 thousand) (CNY100,000 thousand)	\$807,220 (CNY189,000 thousand)	—	5.76%	\$54,691,127	Y	N	Y	(Note 3)
0	ASIA VITAL COMPONENTS CO.,LTD	AVC TECH. (VIETNAM) CO., LTD.	2	\$36,460,751	\$18,845,455 (USD619,000 thousand)	\$18,845,455 (USD619,000 thousand)	\$8,698,765 (USD195,254 thousand) (VND2,416,016,592 thousand)	—	51.69%	\$54,691,127	Y	N	N	(Note 3)

Note 1 : Companies are coded as follows:

- (1) ASIA VITAL COMPONENTS Co., LTD. is coded "0".
- (2) The investees are coded from "1" in the order presented in the table above.

Note 2 : The relationships between endorsement/guarantee providers and guaranteed parties are categorized into the following types :

- (1) A company that has a business relationship with AVC.
- (2) A subsidiary in which AVC holds directly over 50% of common equity interest.
- (3) An investee in which AVC and its subsidiaries jointly hold over 50% of common equity interest.
- (4) A parent company that holds directly over 90% or indirectly over 90% through a subsidiary of the company's common equity interest.
- (5) A company that has provided guarantees to AVC, and vice versa, due to contractual requirements.
- (6) A company in which AVC jointly invests with other shareholders, and for which AVC has provided endorsement/guarantee in proportion to its shareholding percentage.
- (7) Companies in the same industry provide among themselves joint and several security for a performance guarantee of a sales contract for pre-construction homes pursuant to the Consumer Protection Act for each other.

Note 3 : ASIA VITAL COMPONENTS CO.,LTD. : The aggregate amount of endorsements/guarantees for any single entity shall not exceed 20% of the Company's net worth, and the aggregate amount of endorsements/guarantees for any single overseas associated company shall not exceed 100% of the Company's equity net worth.

The overall amount of guarantees/endorsements shall not exceed 150% of the Company's equity net worth.

Note 4 : ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD., ASIA VITAL COMPONENTS (CHINA) CO., LTD., ASIA VITAL COMPONENTS (CHENGDU) CO., LTD., AVC OPTICS (WUHAN) CORP., ASIA VITAL COMPONENTS (DONGGUAN) CO., LTD., AVC PRECISION, CO., LTD. :

The amount of guarantees/endorsements provided to any single entity shall not exceed USD200 million dollars.

FOSITEK CORP. : The aggregate amount of endorsements/guarantees for any single overseas associated company shall not exceed 100% of the Company's equity net worth. The overall amount of guarantees/endorsements shall not exceed 150% of the Company's equity net worth.

Note5 : AVC OPTICS (WUHAN) CORP., ASIA VITAL COMPONENTS (CHENGDU) CO., LTD., ASIA VITAL COMPONENTS (CHINA) CO., LTD., jointly guaranteed to ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD., is CNY170 million dollars. The above table separately presents the resulting in double calculation of the closing balance.

It is a joint endorsement guarantee for obtaining a single line of credit in substance.

Note6 : ASIA VITAL COMPONENTS (WUHAN) CO., LTD., ASIA VITAL COMPONENTS (CHENGDU) CO., LTD.,ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD., jointly guaranteed to ASIA VITAL COMPONENTS (CHINA) CO., LTD., is CNY230 million dollars. The above table separately presents the resulting in double calculation of the closing balance.

It is a joint endorsement guarantee for obtaining a single line of credit in substance.

Note7 : ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD., ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD. ASIA VITAL COMPONENTS (CHINA) CO., LTD., jointly guaranteed to AVC PRECISION, CO., LTD. is CNY80 million dollars. The above table separately presents the resulting in double calculation of the closing balance.

It is a joint endorsement guarantee for obtaining a single line of credit in substance.

Note8 : ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD., AVC PRECISION, CO., LTD. ASIA VITAL COMPONENTS (CHINA) CO., LTD., jointly guaranteed to ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD. is CNY70 million dollars. The above table separately presents the resulting in double calculation of the closing balance.

It is a joint endorsement guarantee for obtaining a single line of credit in substance.

Note9 : AVC PRECISION, CO., LTD. ASIA VITAL COMPONENTS (CHINA) CO., LTD., jointly guaranteed to ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD. is CNY40 million dollars. The above table separately presents the resulting in double calculation of the closing balance. It is a joint endorsement guarantee for obtaining a single line of credit in substance.

Note10 : ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD. ASIA VITAL COMPONENTS (CHINA) CO., LTD., jointly guaranteed to AVC PRECISION, CO., LTD. is CNY27million dollars. The above table separately presents the resulting in double calculation of the closing balance. It is a joint endorsement guarantee for obtaining a single line of credit in substance.

Note11 : Maximum balance of endorsements/guarantees provided to others for current period.

Note12 : The maximum balance for the period and ending balance represent the amounts approved by the Board Directors.

Note13 : The company which endorsements/guarantees by AVC should disclosed the amount actually drawn within ending balance.

Note14 : Public company provided endorsements/guarantees to subsidiary or subsidiary provided endorsements/guarantees to public company or provided endorsements/guarantees which located in CHINA area coded "Y".

ASIA VITAL COMPONENTS CO., LTD AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE-MONTH PERIOD ENDED SEPTEMBER 30, 2025
(Expressed in thousands of New Taiwan Dollars unless Otherwise Specified)
ENDORSEMENT/GUARANTEE PROVIDED TO OTHERS

TABLE 2-1

No (Note 1)	Endorsement/Guarantee Provider	Guaranteed Party		Limits on Endorsement/Guarantee Amount Provided to Each Guaranteed Party (Note 3&4)	Maximum Balance for the Period (Note 11)	Ending Balance (Note 12)	Amount Actually Drawn (Note 13)	Amount of Endorsement/ Guarantee secured by Properties	Accumulated Outflow of Investment from Taiwan as of Sep 30, 2024	Maximum Endorsement/ Guarantee Amount Allowed (Note 3&4)	Endorsement provided by parent company to subsidiaries (Note 14)	Endorsement provided by subsidiaries to parent company (Note 14)	Carrying Amount as of Sep 30, 2025 (Note 14)	Note
		Name	Nature of Relationship (Note 2)											
1	AVC OPTICS (WUHAN) CORP.	ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD.	4	\$6,089,000 (USD200,000 thousand)	\$726,071 (CNY170,000 thousand)	\$726,071 (CNY170,000 thousand)	\$721,124 (CNY168,842 thousand)	—	19.47%	\$6,089,000 (USD200,000 thousand)	N	N	Y	(Note 4・5)
1	AVC OPTICS (WUHAN) CORP.	ASIA VITAL COMPONENTS (CHINA) CO., LTD.	4	\$6,089,000 (USD200,000 thousand)	\$982,331 (CNY230,000 thousand)	\$982,331 (CNY230,000 thousand)	\$666,096 (CNY155,958 thousand)	—	26.34%	\$6,089,000 (USD200,000 thousand)	N	N	Y	(Note 4・6)
2	ASIA VITAL COMPONENTS (CHENGDU) CO., LTD.	ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD.	4	\$6,089,000 (USD200,000 thousand)	\$726,071 (CNY170,000 thousand)	\$726,071 (CNY170,000 thousand)	\$721,124 (CNY168,842 thousand)	—	36.08%	\$6,089,000 (USD200,000 thousand)	N	N	Y	(Note 4・5)
2	ASIA VITAL COMPONENTS (CHENGDU) CO., LTD.	ASIA VITAL COMPONENTS (CHINA) CO., LTD.	4	\$6,089,000 (USD200,000 thousand)	\$982,331 (CNY230,000 thousand)	\$982,331 (CNY230,000 thousand)	\$666,096 (CNY155,958 thousand)	—	48.82%	\$6,089,000 (USD200,000 thousand)	N	N	Y	(Note 4・6)
3	ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD.	AVC OPTICS (WUHAN) CORP.	4	\$6,089,000 (USD200,000 thousand)	\$1,281,301 (CNY300,000 thousand)	\$1,281,301 (CNY300,000 thousand)	\$253,797 (CNY59,423 thousand)	—	17.95%	\$6,089,000 (USD200,000 thousand)	N	N	Y	(Note 4)
3	ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD.	AVC PRECISION, CO., LTD.	4	\$6,089,000 (USD200,000 thousand)	\$341,680 (CNY80,000 thousand)	\$341,680 (CNY80,000 thousand)	\$273,249 (CNY63,978 thousand)	—	4.79%	\$6,089,000 (USD200,000 thousand)	N	N	Y	(Note 4・7)
3	ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD.	ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD.	4	\$6,089,000 (USD200,000 thousand)	\$298,970 (CNY70,000 thousand)	\$298,970 (CNY70,000 thousand)	\$253,358 (CNY59,320 thousand)	—	4.19%	\$6,089,000 (USD200,000 thousand)	N	N	Y	(Note 4・8)
3	ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD.	ASIA VITAL COMPONENTS (CHINA) CO., LTD.	4	\$6,089,000 (USD200,000 thousand)	\$2,050,082 (CNY480,000 thousand)	\$2,050,082 (CNY480,000 thousand)	\$1,026,195 (CNY240,270 thousand)	—	28.72%	\$6,089,000 (USD200,000 thousand)	N	N	Y	(Note 4・6)
4	AVC PRECISION, CO., LTD.	ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD.	3	\$6,089,000 (USD200,000 thousand)	\$1,920,542 (CNY449,670 thousand)	\$1,920,542 (CNY449,670 thousand)	\$1,229,506 (CNY287,873 thousand)	—	121.09%	\$6,089,000 (USD200,000 thousand)	N	N	Y	(Note 4・8・9)

Note 1 : Companies are coded as follows:

- (1) ASIA VITAL COMPONENTS Co., LTD. is coded "0".
- (2) The investees are coded from "1" in the order presented in the table above.

Note 2 : The relationships between endorsement/guarantee providers and guaranteed parties are categorized into the following types :

- (1) A company that has a business relationship with AVC.
- (2) A subsidiary in which AVC holds directly over 50% of common equity interest.
- (3) An investee in which AVC and its subsidiaries jointly hold over 50% of common equity interest.
- (4) A parent company that holds directly over 90% or indirectly over 90% through a subsidiary of the company's common equity interest.
- (5) A company that has provided guarantees to AVC, and vice versa, due to contractual requirements.
- (6) A company in which AVC jointly invests with other shareholders, and for which AVC has provided endorsement/guarantee in proportion to its shareholding percentage.
- (7) Companies in the same industry provide among themselves joint and several security for a performance guarantee of a sales contract for pre-construction homes pursuant to the Consumer Protection Act for each other.

Note 3 : ASIA VITAL COMPONENTS CO.,LTD. : The aggregate amount of endorsements/guarantees for any single entity shall not exceed 20% of the Company's net worth, and the aggregate amount of endorsements/guarantees for any single overseas associated company shall not exceed 100% of the Company's equity net worth.

The overall amount of guarantees/endorsements shall not exceed 150% of the Company's equity net worth.

Note 4 : ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD., ASIA VITAL COMPONENTS (CHINA) CO., LTD., ASIA VITAL COMPONENTS (CHENGDU) CO., LTD., AVC OPTICS (WUHAN) CORP., ASIA VITAL COMPONENTS (DONGGUAN) CO., LTD., AVC PRECISION, CO., LTD. :

The amount of guarantees/endorsements provided to any single entity shall not exceed USD200 million dollars.

FOSITEK CORP. : The aggregate amount of endorsements/guarantees for any single overseas associated company shall not exceed 100% of the Company's equity net worth. The overall amount of guarantees/endorsements shall not exceed 150% of the Company's equity net worth.

Note5 : AVC OPTICS (WUHAN) CORP., ASIA VITAL COMPONENTS (CHENGDU) CO., LTD., ASIA VITAL COMPONENTS (CHINA) CO., LTD., jointly guaranteed to ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD., is CNY170 million dollars. The above table separately presents the resulting in double calculation of the closing balance.

It is a joint endorsement guarantee for obtaining a single line of credit in substance.

Note6 : ASIA VITAL COMPONENTS (WUHAN) CO., LTD., ASIA VITAL COMPONENTS (CHENGDU) CO., LTD., ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD., jointly guaranteed to ASIA VITAL COMPONENTS (CHINA) CO., LTD., is CNY230 million dollars. The above table separately presents the resulting in double calculation of the closing balance.

It is a joint endorsement guarantee for obtaining a single line of credit in substance.

Note7 : ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD., ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD. ASIA VITAL COMPONENTS (CHINA) CO., LTD., jointly guaranteed to AVC PRECISION, CO., LTD. is CNY80 million dollars. The above table separately presents the resulting in double calculation of the closing balance.

It is a joint endorsement guarantee for obtaining a single line of credit in substance.

Note8 : ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD., AVC PRECISION, CO., LTD. ASIA VITAL COMPONENTS (CHINA) CO., LTD., jointly guaranteed to ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD. is CNY70 million dollars. The above table separately presents the resulting in double calculation of the closing balance.

It is a joint endorsement guarantee for obtaining a single line of credit in substance.

Note9 : AVC PRECISION, CO., LTD. ASIA VITAL COMPONENTS (CHINA) CO., LTD., jointly guaranteed to ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD. is CNY40 million dollars. The above table separately presents the resulting in double calculation of the closing balance. It is a joint endorsement guarantee for obtaining a single line of credit in substance.

Note10 : ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD. ASIA VITAL COMPONENTS (CHINA) CO., LTD., jointly guaranteed to AVC PRECISION, CO., LTD. is CNY27million dollars. The above table separately presents the resulting in double calculation of the closing balance. It is a joint endorsement guarantee for obtaining a single line of credit in substance.

Note11 : Maximum balance of endorsements/guarantees provided to others for current period.

Note12 : The maximum balance for the period and ending balance represent the amounts approved by the Board Directors.

Note13 : The company which endorsements/guarantees by AVC should disclosed the amount actually drawn within ending balance.

Note14 : Public company provided endorsements/guarantees to subsidiary or subsidiary provided endorsements/guarantees to public company or provided endorsements/guarantees which located in CHINA area coded "Y".

ASIA VITAL COMPONENTS CO., LTD AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE-MONTH PERIOD ENDED SEPTEMBER 30, 2025
(Expressed in thousands of New Taiwan Dollars unless Otherwise Specified)
ENDORSEMENT/GUARANTEE PROVIDED TO OTHERS

TABLE 2-2

No (Note 1)	Endorsement/Guarantee Provider	Guaranteed Party		Limits on Endorsement/Guarantee Amount Provided to Each Guaranteed Party (Note 3&4)	Maximum Balance for the Period (Note 11)	Ending Balance (Note 12)	Amount Actually Drawn (Note 13)	Amount of Endorsement/ Guarantee secured by Properties	Accumulated Outflow of Investment from Taiwan as of Sep 30, 2025	Maximum Endorsement/ Guarantee Amount Allowed (Note 3&4)	Endorsement provided by parent company to subsidiaries (Note 14)	Endorsement provided by subsidiaries to parent company (Note 14)	Carrying Amount as of Sep 30, 2025 (Note 14)	Note
		Name	Nature of Relationship (Note 2)											
5	ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD.	AVC PRECISION, CO., LTD.	2	\$6,089,000 (USD200,000 thousand)	\$1,538,288 (CNY360,170 thousand)	\$1,538,288 (CNY360,170 thousand)	\$943,414 (CNY220,888 thousand)	—	30.52%	\$6,089,000 (USD200,000 thousand)	N	N	Y	(Note 4、7、10)
6	ASIA VITAL COMPONENTS (CHINA) CO., LTD.	AVC OPTICS (WUHAN) CORP.	4	\$6,089,000 (USD200,000 thousand)	\$213,550 (CNY50,000 thousand)	\$213,550 (CNY50,000 thousand)	\$60,884 (CNY14,255 thousand)	—	2.97%	\$6,089,000 (USD200,000 thousand)	N	N	Y	(Note 4)
6	ASIA VITAL COMPONENTS (CHINA) CO., LTD.	ASIA VITAL COMPONENTS (CHENGDU) CO., LTD.	4	\$6,089,000 (USD200,000 thousand)	\$427,100 (CNY100,000 thousand)	\$427,100 (CNY100,000 thousand)	\$201,497 (CNY47,178 thousand)	—	5.93%	\$6,089,000 (USD200,000 thousand)	N	N	Y	(Note 4)
6	ASIA VITAL COMPONENTS (CHINA) CO., LTD.	ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD.	4	\$6,089,000 (USD200,000 thousand)	\$1,580,272 (CNY370,000 thousand)	\$1,580,272 (CNY370,000 thousand)	\$1,491,750 (CNY349,274 thousand)	—	21.95%	\$6,089,000 (USD200,000 thousand)	N	N	Y	(Note 4、5)
6	ASIA VITAL COMPONENTS (CHINA) CO., LTD.	AVC PRECISION, CO., LTD.	4	\$6,089,000 (USD200,000 thousand)	\$456,997 (CNY107,000 thousand)	\$456,997 (CNY107,000 thousand)	\$273,249 (CNY63,978 thousand)	—	6.35%	\$6,089,000 (USD200,000 thousand)	N	N	Y	(Note 4、7、10)
6	ASIA VITAL COMPONENTS (CHINA) CO., LTD.	ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD.	4	\$6,089,000 (USD200,000 thousand)	\$469,810 (CNY110,000 thousand)	\$469,810 (CNY110,000 thousand)	\$253,358 (CNY59,320 thousand)	—	6.53%	\$6,089,000 (USD200,000 thousand)	N	N	Y	(Note 4、8、9)
7	FOSITEK CORP.	SHENZHEN FOSITEK TELECOM CO.,LTD.	2	\$6,188,943 (USD3,000 thousand)	\$411,660 (CNY75,000 thousand)	\$320,325 (CNY75,000 thousand)	—	—	5.18%	\$9,283,414	N	N	Y	(Note 4)
7	FOSITEK CORP.	FOSITEK (VIET NAM) COMPANY LIMITED	2	\$6,188,943 (USD46,000 thousand)	\$1,400,470 (USD46,000 thousand)	\$1,400,470 (USD46,000 thousand)	\$23,066 (CNY758 thousand)	—	22.63%	\$9,283,414	N	N	N	(Note 4)

Note 1 : Companies are coded as follows:

- (1) ASIA VITAL COMPONENTS Co., LTD. is coded "0".
- (2) The investees are coded from "1" in the order presented in the table above.

Note 2 : The relationships between endorsement/guarantee providers and guaranteed parties are categorized into the following types :

- (1) A company that has a business relationship with AVC.
- (2) A subsidiary in which AVC holds directly over 50% of common equity interest.
- (3) An investee in which AVC and its subsidiaries jointly hold over 50% of common equity interest.
- (4) A parent company that holds directly over 90% or indirectly over 90% through a subsidiary of the company's common equity interest.
- (5) A company that has provided guarantees to AVC, and vice versa, due to contractual requirements.
- (6) A company in which AVC jointly invests with other shareholders, and for which AVC has provided endorsement/guarantee in proportion to its shareholding percentage.
- (7) Companies in the same industry provide among themselves joint and several security for a performance guarantee of a sales contract for pre-construction homes pursuant to the Consumer Protection Act for each other.

Note 3 : ASIA VITAL COMPONENTS CO.,LTD. : The aggregate amount of endorsements/guarantees for any single entity shall not exceed 20% of the Company's net worth, and the aggregate amount of endorsements/guarantees for any single overseas associated company shall not exceed 100% of the Company's equity net worth.

The overall amount of guarantees/endorsements shall not exceed 150% of the Company's equity net worth.

Note 4 : ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD., ASIA VITAL COMPONENTS (CHINA) CO., LTD., ASIA VITAL COMPONENTS (CHENGDU) CO., LTD., AVC OPTICS (WUHAN) CORP., ASIA VITAL COMPONENTS (DONGGUAN) CO., LTD., AVC PRECISION, CO., LTD. :

The amount of guarantees/endorsements provided to any single entity shall not exceed USD200 million dollars.

FOSITEK CORP. : The aggregate amount of endorsements/guarantees for any single overseas associated company shall not exceed 100% of the Company's equity net worth. The overall amount of guarantees/endorsements shall not exceed 150% of the Company's equity net worth.

Note5 : AVC OPTICS (WUHAN) CORP., ASIA VITAL COMPONENTS (CHENGDU) CO., LTD., ASIA VITAL COMPONENTS (CHINA) CO., LTD., jointly guaranteed to ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD., is CNY170 million dollars. The above table separately presents the resulting in double calculation of the closing balance.

It is a joint endorsement guarantee for obtaining a single line of credit in substance.

Note6 : ASIA VITAL COMPONENTS (WUHAN) CO., LTD., ASIA VITAL COMPONENTS (CHENGDU) CO., LTD., ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD., jointly guaranteed to ASIA VITAL COMPONENTS (CHINA) CO., LTD., is CNY230 million dollars. The above table separately presents the resulting in double calculation of the closing balance.

It is a joint endorsement guarantee for obtaining a single line of credit in substance.

Note7 : ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD., ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD. ASIA VITAL COMPONENTS (CHINA) CO., LTD., jointly guaranteed to AVC PRECISION, CO., LTD. is CNY80 million dollars. The above table separately presents the resulting in double calculation of the closing balance.

It is a joint endorsement guarantee for obtaining a single line of credit in substance.

Note8 : ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD., AVC PRECISION, CO., LTD. ASIA VITAL COMPONENTS (CHINA) CO., LTD., jointly guaranteed to ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD. is CNY70 million dollars. The above table separately presents the resulting in double calculation of the closing balance.

It is a joint endorsement guarantee for obtaining a single line of credit in substance.

Note9 : AVC PRECISION, CO.,LTD. ASIA VITAL COMPONENTS (CHINA) CO., LTD., jointly guaranteed to ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD. is CNY40 million dollars. The above table separately presents the resulting in double calculation of the closing balance. It is a joint endorsement guarantee for obtaining a single line of credit in substance.

Note10 : ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD. ASIA VITAL COMPONENTS (CHINA) CO., LTD., jointly guaranteed to AVC PRECISION, CO., LTD. is CNY27million dollars. The above table separately presents the resulting in double calculation of the closing balance. It is a joint endorsement guarantee for obtaining a single line of credit in substance.

Note11 : Maximum balance of endorsements/guarantees provided to others for current period.

Note12 : The maximum balance for the period and ending balance represent the amounts approved by the Board Directors.

Note13 : The company which endorsements/guarantees by AVC should disclosed the amount actually drawn within ending balance.

Note14 : Public company provided endorsements/guarantees to subsidiary or subsidiary provided endorsements/guarantees to public company or provided endorsements/guarantees which located in CHINA area coded "Y".

ASIA VITAL COMPONENTS CO., LTD AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE NINE-MONTH PERIOD ENDED SEPTEMBER 30, 2025

(Expressed in thousands of New Taiwan Dollars unless Otherwise Specified)

MARKETABLE SECURITIES HELD (EXCLUDING INVESTMENTS IN SUBSIDIARIES, ASSOCIATES AND JOINTLY CONTROLLED ENTITIES)

TABLE 3

Name of Held Company	Type and name of Marketable Securities (Note 1)	Relationship with the Company (Note 2)	Financial Statement Account	Sep 30, 2025			
				Shares (In thousands)	Carrying Amount (Note 3)	Percentage of Ownership	Market Value (Note 4)
ASIA VITAL COMPONENTS CO.,LTD	Listed (OTC) stocks						
	UBIQCONN TECHNOLOGY, INC.	—	Financial assets measured at fair value through other comprehensive income, noncurrent	4,140	\$247,587	4.81%	\$247,587
	Not listed (OTC) stocks						
	RTR-TECH TECHNOLOGY CO., LTD.	—	Financial assets measured at fair value through other comprehensive income, noncurrent	14,000	—	19.42%	—
	APTOS TECHNOLOGY INC.	—	Financial assets measured at fair value through other comprehensive income, noncurrent	180	—	0.74%	—
MERIT TRADING CORPORATION	WK TECHNOLOGY FUND IX II LTD.	—	Financial assets measured at fair value through other comprehensive income, noncurrent	3,000	\$30,221	2.67%	\$30,221
	Not listed (OTC) stocks						
	FURUKAWA ELECTRIC (SHENZHEN) CO., LTD.	Other related parties	Financial assets measured at fair value through other comprehensive income, noncurrent	(Note 6)	\$114,654	9.06%	\$114,654
MACE TECH CORP.	Not listed (OTC) stocks						
	SHENG-SHING WORLDWIDE CORP.	—	Financial assets measured at fair value through other comprehensive income, noncurrent	703	\$9,436	14.06%	\$9,436
ASIA VITAL COMPONENTS (CHINA) CO., LTD.	Not listed (OTC) stocks						
	SHENZHEN TIMELINK TECHNOLOGY CO., LTD.	—	Financial assets measured at fair value through other comprehensive income, noncurrent	2,273	—	10.80%	—
FOSITEK CORP.	Listed (TWSE) stocks						
	O-BANK	—	Financial assets measured at fair value through other comprehensive income, noncurrent	6,000	\$71,400	0.18%	\$71,400

Note 1 : The term marketable security shall denote shares, bonds, beneficiary certificates, and any marketable security derived therefrom, to the extent that such instruments fall within the scope of International Financial Reporting Standard (IFRS) 9, Financial Instruments.

Note 2 : If the issuer of the marketable security is not a related party, the corresponding column may be left blank.

Note 3: For securities measured at fair value, the column for carrying value should reflect the balance after fair value adjustments and deduction of accumulated impairment. For securities not measured at fair value, the column should show the original acquisition cost or amortized cost, net of accumulated impairment.

Note 4: The number of shares of securities and their amounts pledged as security or pledged for loans and their restrictions on use under some agreements should be stated in the footnote if the securities presented herein have such conditions.

Note 5: This table lists the securities that the company, in applying the principle of materiality, has determined should be presented.

Note 6: None amount of shares is issued publicly by Limited Company.

ASIA VITAL COMPONENTS CO., LTD AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE-MONTH PERIOD ENDED SEPTEMBER 30, 2025
(Expressed in thousands of New Taiwan Dollars unless Otherwise Specified)
RELATED PARTY TRANSACTIONS WITH PURCHASE OR SALES AMOUNT OF AT LEAST NT\$100 MILLION OR 20% OF THE PAID-IN CAPITAL

TABLE 4

Company Name	Related Party	Nature of Relationships	Transaction Details				Abnormal Transaction		Accumulated Outflow of Investment from Taiwan as of Sep 30, 2025		Note
			Purchases/ Sales	Amount	Percentage to Total	Collection/ Payment Terms	Unit Price	Collection/ Payment Terms	Ending Balance	Percentage to Total	
ASIA VITAL COMPONENTS CO., LTD	ASIA VITAL COMPONENTS (CHENGDU) CO., LTD.	Subsidiary	(Purchases)	(\$1,067,524)	(1%)	Net 90 days from the end of the month of when invoice is issued by T/T	N/A	N/A	(\$460,356)	(1%)	
ASIA VITAL COMPONENTS CO., LTD	ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD.	Subsidiary	(Purchases)	(\$19,591,203)	(26%)	Net 90 days from the end of the month of when invoice is issued by T/T	N/A	N/A	(\$10,766,944)	(34%)	
ASIA VITAL COMPONENTS CO., LTD	AVC OPTICS (WUHAN) CORP.	Subsidiary	(Purchases)	(\$4,916,783)	(7%)	Net 60 days from the end of the month of when invoice is issued by T/T	N/A	N/A	(\$2,722,350)	(9%)	
ASIA VITAL COMPONENTS CO., LTD	ASIA VITAL COMPONENTS (CHINA) CO., LTD.	Subsidiary	(Purchases)	(\$517,424)	(1%)	Net 90 days from the end of the month of when invoice is issued by T/T	N/A	N/A	(\$193,308)	(1%)	
ASIA VITAL COMPONENTS CO., LTD	ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD.	Subsidiary	(Purchases)	(\$23,462,262)	(31%)	Net 60 days from the end of the month of when invoice is issued by T/T	N/A	N/A	(\$9,237,545)	(29%)	
ASIA VITAL COMPONENTS CO., LTD	(JIASHAN) D-MAX ELECTRONICS CO.,LTD.	Subsidiary	(Purchases)	(\$1,117,271)	(1%)	Net 30 days from the end of the month of when invoice is issued by T/T	N/A	N/A	(\$673,246)	(2%)	
ASIA VITAL COMPONENTS CO., LTD	AVC TECH. (VIETNAM) CO., LTD.	Subsidiary	(Purchases)	(\$22,062,410)	(30%)	Net 30 days from the end of the month of when invoice is issued by T/T	N/A	N/A	(\$6,811,714)	(21%)	
ASIA VITAL COMPONENTS CO., LTD	AVC AMERICA, INC.	Subsidiary	Sales	\$2,183,955	3%	Net 60 days from the end of the month of when invoice is issued by T/T	N/A	N/A	\$422,756	8%	

(Continued)

ASIA VITAL COMPONENTS CO., LTD AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE-MONTH PERIOD ENDED SEPTEMBER 30, 2025
(Expressed in thousands of New Taiwan Dollars unless Otherwise Specified)
RELATED PARTY TRANSACTIONS WITH PURCHASE OR SALES AMOUNT OF AT LEAST NT\$100 MILLION OR 20% OF THE PAID-IN CAPITAL

TABLE 4-1

Company Name	Related Party	Nature of Relationships	Transaction Details				Abnormal Transaction		Accumulated Outflow of Investment from Taiwan as of Sep 30, 2025		Note
			Purchases/ Sales	Amount	Percentage to Total	Collection/ Payment Terms	Unit Price	Collection/ Payment Terms	Ending Balance	Percentage to Total	
ASIA VITAL COMPONENTS (CHENGDU) CO., LTD.	ASIA VITAL COMPONENTS CO., LTD	The company's ultimate parent	Sales	\$1,067,524	85%	Net 90 days from the end of the month of when invoice is issued by T/T	N/A	N/A	\$460,556	82%	
ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD.	ASIA VITAL COMPONENTS CO., LTD	The company's ultimate parent	Sales	\$19,591,203	90%	Net 90 days from the end of the month of when invoice is issued by T/T	N/A	N/A	\$10,766,944	92%	
AVC OPTICS (WUHAN) CORP.	ASIA VITAL COMPONENTS CO., LTD	The company's ultimate parent	Sales	\$4,916,783	81%	Net 60 days from the end of the month of when invoice is issued by T/T	N/A	N/A	\$2,722,350	87%	
ASIA VITAL COMPONENTS (CHINA) CO., LTD.	ASIA VITAL COMPONENTS CO., LTD	The company's ultimate parent	Sales	\$517,424	5%	Net 90 days from the end of the month of when invoice is issued by T/T	N/A	N/A	\$193,308	5%	
ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD.	ASIA VITAL COMPONENTS CO., LTD	The company's ultimate parent	Sales	\$23,462,262	92%	Net 60 days from the end of the month of when invoice is issued by T/T	N/A	N/A	\$9,237,545	84%	
(JIASHAN) D-MAX ELECTRONICS CO.,LTD.	ASIA VITAL COMPONENTS CO., LTD	The company's ultimate parent	Sales	\$1,117,271	88%	Net 30 days from the end of the month of when invoice is issued by T/T	N/A	N/A	\$673,246	91%	
AVC TECH. (VIETNAM) CO., LTD.	ASIA VITAL COMPONENTS CO., LTD	The company's ultimate parent	Sales	\$21,601,189	100%	Net 30 days from the end of the month of when invoice is issued by T/T	N/A	N/A	\$6,811,714	95%	
AVC AMERICA, INC.	ASIA VITAL COMPONENTS CO., LTD	The company's ultimate parent	(Purchases)	(\$2,181,886)	(100%)	Net 60 days from the end of the month of when invoice is issued by T/T	N/A	N/A	(\$422,756)	(99%)	

ASIA VITAL COMPONENTS CO., LTD AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE-MONTH PERIOD ENDED SEPTEMBER 30, 2025
(Expressed in thousands of New Taiwan Dollars unless Otherwise Specified)
RECEIVABLES FROM RELATED PARTIES OF AT LEAST NT\$100 MILLION OR 20% OF THE PAID-IN CAPITAL

TABLE 5

Company Name	Related Party	Nature of Relationships	Ending Balance (Note 3)	Turnover Ratio (times)	Overdue		Amounts Received in Subsequent Periods	Allowance for Doubtful Accounts
					Amount	Action Taken		
ASIA VITAL COMPONENTS (CHENGDU) CO., LTD.	ASIA VITAL COMPONENTS CO., LTD	The company's ultimate parent	\$460,556	2.15	—	(Note 2)	\$86,903	(Note 1)
ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD.	ASIA VITAL COMPONENTS CO., LTD	The company's ultimate parent	\$10,766,944	2.15	—	(Note 2)	\$3,538,881	(Note 1)
AVC OPTICS (WUHAN) CORP.	ASIA VITAL COMPONENTS CO., LTD	The company's ultimate parent	\$2,722,350	2.92	—	(Note 2)	\$1,201,721	(Note 1)
ASIA VITAL COMPONENTS (CHINA) CO., LTD.	ASIA VITAL COMPONENTS CO., LTD	The company's ultimate parent	\$193,308	2.41	—	(Note 2)	\$38,326	(Note 1)
ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD.	ASIA VITAL COMPONENTS CO., LTD	The company's ultimate parent	\$9,237,545	3.18	—	(Note 2)	\$3,079,285	(Note 1)
(JIASHAN) D-MAX ELECTRONICS CO.,LTD.	ASIA VITAL COMPONENTS CO., LTD	The company's ultimate parent	\$673,246	1.85	—	(Note 2)	\$149,993	(Note 1)
AVC TECH. (VIETNAM) CO., LTD.	ASIA VITAL COMPONENTS CO., LTD	The company's ultimate parent	\$6,811,714	4.49	—	(Note 2)	\$3,459,328	(Note 1)
ASIA VITAL COMPONENTS CO., LTD	AVC AMERICA, INC.	Subsidiary	(\$422,756)	4.05	—	(Note 2)	—	(Note 1)

Note 1 : The preparation of consolidated statements does not require recording the allowance for doubtful accounts.

Note 2 : The Company balances its accounts regularly and writes off receivables against payables.

Note 3 : All the above transactions were eliminated on consolidation.

ASIA VITAL COMPONENTS CO., LTD AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE-MONTH PERIOD ENDED SEPTEMBER 30, 2025
(Expressed in thousands of New Taiwan Dollars unless Otherwise Specified)
NAMES, LOCATIONS AND RELATED INFORMATION OF INVESTEE COMPANIES (Not including investment in Mainland China)

TABLE 6

Investor Company	Investee Company	Address	Main businesses and products	Initial Investment		Investment as of Sep 30, 2025			Accumulated Outflow of Investment from Taiwan as of Sep 30, 2025	Investment income (loss) recognized	Note
				Ending balance	Beginning balance	Number of shares (thousand)	Percentage of ownership (%)	Carrying amount			
ASIA VITAL COMPONENTS CO., LTD	AVC INTERNATIONAL CO., LTD. – B.V.I.	British Virgin Islands	Investment holding	\$5,147,294	\$5,147,294	16	100.00%	\$15,637,148	\$3,075,864	\$2,182,918	
	CHIHUNG INTERNATIONAL LTD.	Samoa	Investment holding	\$1,040,647	\$1,040,647	32,770	100.00%	\$7,461,518	\$603,997	\$611,579	
	MERIT TRADING CORPORATION	Samoa	Trade	\$29,088	\$29,088	892	100.00%	\$111,749	—	—	
	RAYNEY INTERNATIONAL LTD.	Samoa	Trade	\$78,950	\$78,950	2,400	100.00%	\$348,602	\$71,443	\$71,443	
	AVC AMERICA, INC.	USA	Trade	\$91,903	\$91,903	41	100.00%	\$264,022	\$49,559	\$49,559	
	AVC INTERNATIONAL (SAMOA) CO., LTD.	Samoa	Trade	\$10,157	\$10,157	300	100.00%	\$12,569	\$749	\$843	
	JADS CORPORATION (HK) LTD.	Hongkong	Trade	\$327	\$327	10	100.00%	\$27,674	\$101	(\$1,372)	
	ZIMAG TECHNOLOGY CO., INC.	Taoyuan City, Taiwan	Manufacture, process and sales of molds and aluminum products	—	\$45,000	—	—	—	\$20,738	\$2,076	(Note 1)
	AVC INTERNATIONAL CO., LTD. – SAMOA	Samoa	Trade	\$32,120	\$32,120	1,000	100.00%	\$34,277	(\$727)	(\$727)	
	FOSITEK CORP.	New Taipei City, Taiwan	Sales and manufacture of electronic parts, computers and related products	\$209,829	\$209,829	11,567	16.87%	\$1,057,708	\$1,373,798	\$232,403	
	HUNG YE INVESTMENT CO., LTD.	New Taipei City, Taiwan	Investment holding	\$60,000	\$60,000	6,000	100.00%	\$5,428	\$7	\$7	
	D-MAX TECHNOLOGY CO., LTD.	New Taipei City, Taiwan	Sales and manufacture of electronic parts and related products	\$201,035	\$201,035	28,500	100.00%	\$473,019	\$78,502	\$78,219	
	AVC EUROPE TECHNOLOGY GMBH	Germany	Trade	\$9,050	\$9,050	250	100.00%	\$9,363	\$20	\$20	
	AVC TECH. (VIETNAM) CO., LTD.	Vietnam	Sales and manufacture of electronic	\$3,028,417	\$3,028,417	(Note 2)	100.00%	\$2,618,093	\$921,972	\$531,055	
	PARAGON SEMICONDUCTOR LIGHTING TECHNOLOGY CO., LTD.	New Taipei City, Taiwan	Manufacture of industrial lighting equipment	\$30,000	\$50,000	3,000	16.67%	\$21,250	(\$5,878)	(\$2,170)	

Note 1 : The disclosure period of the profit and loss of investee companies is from January 1 ,2025 to June30,2025

Note 2 : None amount of shares is issued publicly by Limited Company.

(Continued)

ASIA VITAL COMPONENTS CO. , LTD AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE-MONTH PERIOD ENDED SEPTEMBER 30, 2025
(Expressed in thousands of New Taiwan Dollars unless Otherwise Specified)
NAMES, LOCATIONS AND RELATED INFORMATION OF INVESTEE COMPANIES (Not including investment in Mainland China)

TABLE 6-1

Investor Company	Investee Company	Address	Main businesses and products	Initial Investment		Investment as of Sep 30, 2025			Accumulated Outflow of Investment from Taiwan as of Sep 30, 2025	Investment income (loss) recognized	Note
				Ending balance	Beginning balance	Number of shares (thousand)	Percentage of ownership (%)	Carrying amount			
AVC INTERNATIONAL CO., LTD. —B.V.I.	MACE TECH CORP.	British Virgin Islands	Trade	\$319,776	\$319,776	11,068	100.00%	\$5,335,826	\$966,133	\$966,133	
	AVC OPTICS CORP.	Cayman Islands	Investment holding	\$3,128,775	\$3,128,775	100,000	100.00%	\$3,728,785	\$675,755	\$675,755	
HUNG YE INVESTMENT CO., LTD.	KEY APPLICATION TECHNOLOGY CO., LTD.	Hsinchu City, Taiwan	Sales and manufacture of electronic products	\$15,300	\$15,300	1,115	16.31%	—	(\$7,414)	—	
D-MAX TECHNOLOGY CO., LTD.	WUCHIDA INTERNATIONAL CO., LTD.	Samoa	Investment holding	\$132,004	\$132,004	4,000	100.00%	\$536,378	\$98,830	\$98,830	
WUCHIDA INTERNATIONAL CO., LTD.	D-MAX INTERNATIONAL CO., LIMITED	Hongkong	Investment holding	\$132,004	\$132,004	4,000	100.00%	\$482,878	\$99,071	\$99,071	
FOSITEK CORP.	MARKETHILL INVESTMENTS LTD.	Samoa	Investment holding	\$949,097	\$949,097	33,200	100.00%	\$5,278,796	\$1,230,294	\$1,214,671	
FOSITEK CORP.	FOSITEK (VIET NAM) COMPANY LIMITED	Vietnam	Sales and manufacture of rails and shafts	\$59,430	\$59,430	(Note)	100.00%	\$467,887	\$200,808	\$109,916	
FOSITEK CORP.	FOSITEK AMERICA, INC.	USA	Sales of rails and shafts	\$14,078	\$14,078	(Note)	100.00%	\$13,780	(\$1,251)	(\$1,251)	

Note : None amount of shares is issued publicly by Limited Company.

ASIA VITAL COMPONENTS CO., LTD AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE-MONTH PERIOD ENDED SEPTEMBER 30, 2025
(Expressed in thousands of New Taiwan Dollars unless Otherwise Specified)
INFORMATION ON INVESTMENT IN MAINLAND CHINA

TABLE 7

Investor Company	Investee Company	Main Businesses and Products	Total Amount of Paid-in Capital	Method of Investment (Note 1)	Accumulated Outflow of Investment from Taiwan as of January 1, 2025	Investment Flows		Accumulated Outflow of Investment from Taiwan as of Sep 30, 2025	Percentage of Ownership (Direct or Indirect Investment)	Profits/ Losses of the Investee Company	Share of Profits/Losses	Carrying Amount as of Sep 30, 2025	Accumulated Inward Remittance of Earnings as of Sep 30, 2025
						Outflow	Inflow						
ASIA VITAL COMPONENTS CO., LTD	ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD.	Sales and manufacture of computers related products and computer cooling fans	\$642,719	(2) AVC INTERNATIONAL CO., LTD. — B.V.I.	\$642,719	—	—	\$642,719	100.00%	\$1,401,514	\$1,401,514	\$7,138,718	—
ASIA VITAL COMPONENTS CO., LTD	FURUKAWA AVC ELECTRONICS (SUZHOU) CO., LTD.	Sales and manufacture of reflow machines, solder paste printers and notebook thermal modules	\$267,247	(2) RAYNEY INTERNATIONAL LTD.	\$54,176	—	—	\$54,176	30.00%	\$237,156	\$71,147	\$182,752	—
ASIA VITAL COMPONENTS CO., LTD	ASIA VITAL COMPONENTS (DONGGUAN) CO., LTD.	Sales and manufacture of computers, electronic products and related parts	\$514,105	(2) AVC INTERNATIONAL CO., LTD. — B.V.I.	\$319,776	—	—	\$319,776	100.00%	\$967,066	\$967,066	\$5,040,145	—
ASIA VITAL COMPONENTS CO., LTD	ASIA VITAL COMPONENTS (CHINA) CO., LTD.	Sales and manufacture of computers related products and computer cooling fans	\$879,291	(2) CHIHUNG INTERNATIONAL LTD.	\$879,291	—	—	\$879,291	100.00%	\$616,367	\$616,367	\$7,198,755	—
ASIA VITAL COMPONENTS CO., LTD	FURUKAWA ELECTRIC (SHENZHEN) CO., LTD.	Sales and manufacture of automobile parts	\$321,060	(2) MERIT TRADING CORPORATION	\$29,088	—	—	\$29,088	9.06%	(\$150,389)	—	\$114,654	—
ASIA VITAL COMPONENTS CO., LTD	ASIA VITAL COMPONENTS (CHENGDU) CO., LTD.	Sales and manufacture of computers, related parts and accessories	\$1,055,897	(2) AVC INTERNATIONAL CO., LTD. — B.V.I.	\$1,055,897	—	—	\$1,055,897	100.00%	\$55,334	\$55,334	\$2,012,163	—
D-MAX TECHNOLOGY CO., LTD.	(JIASHAN)D-MAX ELECTRONICS CO., LTD.	Sales and manufacture of electronic and photographic equipment	\$132,004	(2) WUCHIDA INTERNATIONAL CO., LTD.	\$132,004	—	—	\$132,004	100.00%	\$99,070	\$99,070	\$482,493	—
ASIA VITAL COMPONENTS CO., LTD	AVC OPTICS (WUHAN) CORP.	Sales and manufacture of computers related products and computer cooling fans	\$3,128,775	(2) AVC INTERNATIONAL CO., LTD. — B.V.I.	\$3,128,775	—	—	\$3,128,775	100.00%	\$675,755	\$675,755	\$3,728,772	—
FOSITEK CORP.	SHENZHEN FOSITEK TELECOM CO., LTD.	Sales and manufacture of rails, shafts and metal stamping tooling	\$846,331	(2) MARKETHILL INVESTMENTS LTD.	\$846,331	—	—	\$846,331	100.00%	\$1,254,731	\$1,254,731	\$5,290,650	—

Accumulated Outflow of Investment from Taiwan to Mainland China as of Sep 30, 2025	Investment Amounts Authorized by Investment Commission, MOEA	Upper Limit on Investment
\$7,088,057 (USD 230,093,010)	\$7,938,558 (USD 260,750,828)	(Note 3)

Note 1 : The methods for investment in Mainland China are categorized into the following three types. Please specify the type.

- (1) Direct investment in Mainland China.
- (2) Indirectly investment in Mainland China through companies registered in the third area (Please specify the name of the company in third region).
- (3) Others.

Note 2 : The table is expressed in thousands of New Taiwan Dollars.

Note 3 : The Company has obtained the certificate of being qualified for operating headquarters, issued by the Industrial Development Bureau, MOEA, the ceiling amount of the investment in Mainland China is not applicable to the Company.

Note 4 : All the above transactions were eliminated on consolidation.

ASIA VITAL COMPONENTS CO., LTD AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE-MONTH PERIOD ENDED SEPTEMBER 30, 2025
(Expressed in thousands of New Taiwan Dollars unless Otherwise Specified)
INTERCOMPANY RELATIONSHIPS AND SIGNIFICANT INTERCOMPANY TRANSACTIONS

TABLE 8

No. (Note 1)	Company Name	Counter Party	Nature of Relationship (Note 2)	Intercompany Transactions			
				Financial Statements Item	Amount	Terms	Percentage of Consolidated Net Revenue or Total Assets (Note 3)
0	ASIA VITAL COMPONENTS CO., LTD	AVC AMERICA, INC.	1	Sales	\$2,183,955	General trading terms	2%
0	ASIA VITAL COMPONENTS CO., LTD	AVC AMERICA, INC.	1	Accounts receivable	\$422,756	General trading terms	0%
0	ASIA VITAL COMPONENTS CO., LTD	ASIA VITAL COMPONENTS (CHINA) CO., LTD.	1	Purchases	\$517,424	General trading terms	1%
0	ASIA VITAL COMPONENTS CO., LTD	ASIA VITAL COMPONENTS (CHINA) CO., LTD.	1	Accounts payable	\$193,308	General trading terms	0%
0	ASIA VITAL COMPONENTS CO., LTD	AVC OPTICS (WUHAN) CORP.	1	Purchases	\$4,916,783	General trading terms	5%
0	ASIA VITAL COMPONENTS CO., LTD	AVC OPTICS (WUHAN) CORP.	1	Accounts payable	\$2,722,350	General trading terms	2%
0	ASIA VITAL COMPONENTS CO., LTD	ASIA VITAL COMPONENTS (CHENGDU) CO., LTD.	1	Purchases	\$1,067,524	General trading terms	1%
0	ASIA VITAL COMPONENTS CO., LTD	ASIA VITAL COMPONENTS (CHENGDU) CO., LTD.	1	Accounts payable	\$460,556	General trading terms	0%
0	ASIA VITAL COMPONENTS CO., LTD	ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD.	1	Purchases	\$19,591,203	General trading terms	21%
0	ASIA VITAL COMPONENTS CO., LTD	ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD.	1	Accounts payable	\$10,766,944	General trading terms	8%
0	ASIA VITAL COMPONENTS CO., LTD	ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD.	1	Purchases	\$23,462,262	General trading terms	26%
0	ASIA VITAL COMPONENTS CO., LTD	ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD.	1	Accounts payable	\$9,237,545	General trading terms	7%
0	ASIA VITAL COMPONENTS CO., LTD	AVC TECH. (VIETNAM) CO., LTD.	1	Purchases	\$22,062,410	General trading terms	24%
0	ASIA VITAL COMPONENTS CO., LTD	AVC TECH. (VIETNAM) CO., LTD.	1	Accounts payable	\$6,811,714	General trading terms	5%
0	ASIA VITAL COMPONENTS CO., LTD	(JIASHAN) D-MAX ELECTRONICS CO.,LTD.	1	Purchases	\$1,117,271	General trading terms	1%
0	ASIA VITAL COMPONENTS CO., LTD	(JIASHAN) D-MAX ELECTRONICS CO.,LTD.	1	Accounts payable	\$673,246	General trading terms	0%

Note 1: The information of significant transactions and amounts between the Company and subsidiaries are coded as follows:

- 1.The Company is coded "0".
2. The subsidiaries are coded consecutively beginning from "1" in the order presented in the table above.

Note 2: The relationship between transaction company and counterparty is classified into one of the following three categories:

1. The Company to the consolidated subsidiary.
2. The consolidated subsidiary to the Company.
3. The consolidated subsidiary to another consolidated subsidiary.

Note 3: In calculating the percentage, the transaction amount is divided by consolidated total assets for balance sheet accounts and is divided by consolidated total revenue for income statement accounts.

Note 4: The amount of transactions which is listed in the table is determined by its material.

ASIA VITAL COMPONENTS CO., LTD AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE-MONTH PERIOD ENDED SEPTEMBER 30, 2025
(Expressed in thousands of New Taiwan Dollars unless Otherwise Specified)
INTERCOMPANY RELATIONSHIPS AND SIGNIFICANT INTERCOMPANY TRANSACTIONS

TABLE 8-1

No. (Note 1)	Company Name	Counter Party	Nature of Relationship (Note 2)	Intercompany Transactions			
				Financial Statements Item	Amount	Terms	Percentage of Consolidated Net Revenue or Total Assets (Note 3)
1	AVC PRECISION, CO., LTD.	ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD.	3	Sales	\$4,401,243	General trading terms	5%
1	AVC PRECISION, CO., LTD.	ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD.	3	Accounts receivable	\$1,078,670	General trading terms	1%
1	AVC PRECISION, CO., LTD.	ASIA VITAL COMPONENTS (CHINA) CO., LTD.	3	Sales	\$452,635	General trading terms	0%
1	AVC PRECISION, CO., LTD.	ASIA VITAL COMPONENTS (CHINA) CO., LTD.	3	Accounts receivable	\$44,892	General trading terms	0%
1	AVC PRECISION, CO., LTD.	AVC TECH. (VIETNAM) CO., LTD.	3	Sales	\$422,625	General trading terms	0%
1	AVC PRECISION, CO., LTD.	AVC TECH. (VIETNAM) CO., LTD.	3	Accounts receivable	\$209,957	General trading terms	0%
2	AVC OPTICS (WUHAN) CORP.	JADS CORPORATION (HK) LTD.	3	Sales	\$298,217	General trading terms	0%
2	AVC OPTICS (WUHAN) CORP.	JADS CORPORATION (HK) LTD.	3	Accounts receivable	\$135,638	General trading terms	0%
3	ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD.	ASIA VITAL COMPONENTS (CHINA) CO., LTD.	3	Purchases	\$14,727	General trading terms	0%
3	ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD.	ASIA VITAL COMPONENTS (CHINA) CO., LTD.	3	Accounts payable	\$127,331	General trading terms	0%
3	ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD.	JADS CORPORATION (HK) LTD.	3	Sales	\$955,766	General trading terms	1%
3	ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD.	JADS CORPORATION (HK) LTD.	3	Accounts receivable	\$423,900	General trading terms	0%
3	ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD.	AVC TECH. (VIETNAM) CO., LTD.	3	Purchases	\$418,609	General trading terms	0%
3	ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD.	AVC TECH. (VIETNAM) CO., LTD.	3	Accounts payable	\$458,848	General trading terms	0%
3	ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD.	AVC TECH. (VIETNAM) CO., LTD.	3	Sales	\$956,963	General trading terms	1%
3	ASIA VITAL COMPONENTS (SHEN ZHEN) CO., LTD.	AVC TECH. (VIETNAM) CO., LTD.	3	Accounts receivable	\$875,630	General trading terms	1%
4	CHIHUNG INTERNATIONAL LTD.	JADS CORPORATION (HK) LTD.	3	Other receivable	\$152,225	General trading terms	0%
5	JADS CORPORATION (HK) LTD.	ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD.	3	Sales	\$981,849	General trading terms	1%
5	JADS CORPORATION (HK) LTD.	ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD.	3	Accounts receivable	\$574,602	General trading terms	0%
6	ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD.	AVC TECH. (VIETNAM) CO., LTD.	3	Sales	\$2,077,653	General trading terms	2%
6	ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD.	AVC TECH. (VIETNAM) CO., LTD.	3	Accounts receivable	\$1,599,723	General trading terms	1%
6	ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD.	AVC TECH. (VIETNAM) CO., LTD.	3	Purchases	\$290,571	General trading terms	0%
6	ASIA VITAL COMPONENTS (DONGGUAN) CO.,LTD.	AVC TECH. (VIETNAM) CO., LTD.	3	Accounts payable	\$69,193	General trading terms	0%

Note 1 : The parent company and its subsidiaries are coded as follows:

No.1. The parent company is coded "0".

No.2. The subsidiaries are coded consecutively beginning from "1" in the order presented in the table above.

Note 2 : Transactions are categorized as follows:

No.1. Transactions from parent company to a subsidiary.

No.2. Transactions from subsidiary to the parent company.

No.3. Transactions between subsidiaries.

Note 3 : Regarding the percentage of transaction amount to consolidated net revenue or total assets, it is computed based on the ending balance to consolidated total assets for balance sheet items; and based on interim accumulated amount to consolidated net revenue for income statement items.

Note 4 : The amount of transactions which is listed in the table is determined by its material.